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Synthesis of the norepinephrine distributed to sub-cortical and cortical brain regions 
occurs in the locus coeruleus.  Impaired function results in reduced availability of 
norepinephrine.  Locus coeruleus degeneration is a well-documented feature of 
Alzheimer’s disease; however, the role of catecholaminergic dysfunction remains 
unclear.  Deregulation of this system may accelerate the development and progression 
of Alzheimer’s disease, particularly in patients without familial gene mutations. 
Currently no animal model exists for idiopathic Alzheimer’s disease, which accounts 
for the majority of human cases.  To ascertain the role of the noradrenergic system on 
the development of amyloid pathology and amyloid-β synthesis pathway, female non-
human primates received injection of 40 mg/kg of the neurotoxin DSP4 (N-(2-
chloroethyl)-N-ethyl-2-bromobenzylamine) or vehicle and subsequent injections three 
and six months later (10 mg/kg DSP-4).  At nine months, brain samples were 
processed for catecholamines.  Distribution of amyloid identified by 6E10 and 
  
localization of dopamine β-hydroxylase to visualize locus coeruleus neurons wa
examined using immunostaining in tissue sections.  Brain levels of amyloid precursor 
protein, soluble amyloid-β peptides (1-40 and 1-42) along with β-site APP cleaving 
enzyme-1 were also measured. Results showed norepinephr e depletion in the locus 
coeruleus following DSP4 injection.  Reduction of dpamine β-hydroxylase was 
detected in aged rhesus monkeys after DSP4.  Distribution of amyloid identified by 
6E10 was exacerbated in squirrel monkeys following DSP4 and elevated in aged 
rhesus monkeys after DSP4; additionally DSP4 increased the amyloid-β42 to 
amyloid-β40 ratio in aged rhesus monkeys.  Species specific alterations in amyloid 
precursor protein and β-site amyloid precursor protein cleaving enzyme-1 were 
observed and rhesus monkeys were more sensitive to effects of DSP4.  These data 
provide evidence for a potential mechanism important in Alzheimer’s disease 
pathology development and indicate that decreased norepinephrine contributed to an 
increase in soluble amyloid isoforms and increased accumulation in neocortex in non-
human primates.  Altered amyloid precursor protein processing contributes to 
increased amyloid pathology in the absence of chronic neuroinflammation.  Non-
human primates are an ideal candidate for an animal model because amyloid 
pathology and neurodegenerative disease characteristi s occur naturally later in life, 
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Chapter 1: Review of Relevant Literature 
Central Nervous System 
Introduction 
The interdisciplinary branch of Neuroscience aims to further the study of the 
nervous system, developing experiments to unravel the mystery of the brain and 
diseases that impact its function are at the forefrnt of modern science.  The nervous 
system is the most complex system in the body and neurological diseases represent a 
large and increasing burden; through careful study scientists have made great strides 
in comprehending modes of cellular communication along with mechanisms for 
regulating brain activity and behavior.  Neurons receiving a threshold stimulus from 
neighboring cells transmit an action potential down the axon. Since they do not 
physically contact one another neurons communicate through an extracellular space 
called the synapse.  Electrochemical signaling results in propagation of an electrical 
signal and conversion to chemical release into the synaptic cleft.  These 
neurotransmitters, functioning in both inhibitory and excitatory capacities, act on 
receptors and second messenger systems; this mechanism dramatically amplifies the 
signal.  Levels of neurotransmitters, the receptors, and their action upon signaling 
pathways require balance to maintain proper functio.  Many neurological and 
psychiatric diseases result from imbalances in neurotransmitters or inappropriate 
signaling.  Early studies regarding neurons and interactions between neuronal systems 
by Donald Hebb and later Eric Kandel modernized the study of Neuroscience.  Yet 





downstream consequences of aberrant signaling remains one of the major challenges 
within the field of neuroscience. 
Parts of the central nervous system include the brain and spinal cord, with the 
brain being further divided into brainstem (mesencephalon and rhombencephalon), 
cerebellum (metencephalon) and cerebrum (telencephalon and diencephalon).  
Voluntary actions such as movement, sensory integraion, learning and memory are 
all controlled by activity in the central nervous system. Specific regions are involved 
in regulation of central nervous system activity, though tasks are often interdependent 
on multiple areas.  The largest and most developed region of the brain, the cerebrum, 
is divided into equal hemispheres and further classified into four major lobes: frontal, 
parietal, temporal, and occipital cortex.  Brain tissue can be grossly sub-divided into 
white and grey matter regions, with neuronal cell bodies contained mainly within the 
grey matter neocortex. Ramon y Cajal clearly identified the neuron as the most 
fundamental unit in the brain, using the recently developed Golgi staining method to 
label individual cerebral cortex cells and presenting his work in 1888 (De Carlos and 
Borrell 2007).   
Neurons function as the core of the central nervous system to integrate 
signals, pass on pertinent information and produce outcomes.  Synthesis of specific 
proteins and receptors determine the neuronal physiology and action; two major 
excitatory neurotransmitters include acetylcholine a d norepinephrine, while γ-
aminobutyric acid is the main inhibitory neurotransmitter in the brain.  These 
chemicals are released into the extracellular space and bind to receptors on the post-





neuronal cell bodies and resulting synaptic connections are essential for cellular 
communication and activity regulation.  Neuroglia, such as microglia and astrocytes, 
populate the white matter and are an integral support system in the central nervous 
system.  Microglia are widely distributed throughout the brain and derived from the 
immune system; astrocytes are derived from neural stem cells and integrate neurons 
to the central nervous system blood supply.  Microglia monitor their environment and 
act as resident macrophages in the brain, rapidly altering their morphology and 
proliferating after trauma in order to phagocytize cellular debris (Kettenmann, 
Hanisch et al. 2011; Wake and Fields 2011).   Working together with the blood-brain 
barrier this response is vital to protecting the central nervous system from invading 
pathogens and maintaining homeostasis in the brain after trauma.  Astrocytes also 
provide metabolic and structural support to synapses and the blood-brain barrier; 
regulating the chemical environment of the synapse by removing excess ions and 
neurotransmitters (Sofroniew and Vinters 2010).    
Structure and Function 
The mammalian cortex has a laminated appearance which contains 
distributions of neuronal sub-types.  Neurons vary in morphology, both size and 
shape, and multipolar neurons are the most common in vertebrate systems.  
Functionally organized into vertical columns, six dstinct layers extend from the 
surface of the brain through the gray matter.  Their appearance varies depending on 
their association area with associative fiber tracts connecting regions within a 
hemisphere.  Commissural fiber tracts to the opposite hemisphere traverse the corpus 





maximize grey matter area, the cerebral hemispheres contain multiple involutions 
called sulci which surround gyri to give human and other large mammal brains their 
characteristic appearance.  In higher order primates nd humans, it is believed that 
increased development of neocortex in conjunction with intricate brain networks 
enable more complex social interactions, emotions, a d memory.   
Importantly for neuroanatomical characterization, while there is individual 
variation in smaller sulcal patterning, the large sulci provide consistency for 
nomenclature and identification of neuroanatomical landmarks across subjects.  The 
medial longitudinal fissure divides the cerebral hemispheres and the central sulcus 
divides the frontal lobe from the parietal lobe.  The horizontal lateral sulcus (also 
referred to as the Sylvian fissure or lateral cerebral fissure) divides the temporal lobe 
from the dorsal lobes, while the parieto-occipital sulcus divides the parietal and 
occipital lobes (Figure 1).  Specific delineations are made within each lobe depending 
on the sulci/gyri patterning and cytoarchitectural observations first defined by 
neuroanatomist K. Brodmann in 1909.  Utilizing the Nissl staining method he 
recorded the laminar organization of the neocortex.   Brodmann defined up to 52 
regions in mammalian species, using the same number to label homologous regions 
across species to provide a means of comparison (Zilles and Amunts 2010).  While 
Brodmann is probably the most well-known and his contribution undeniable to the 
study of neuroanatomy, his work has been debated and revised over the last century.  
Numerous groups in the 1990’s used more precise staining methods, including 
antibodies to neurofilament proteins and calcium binding proteins, to better isolate 





Price 1994; Hof, Nimchinsky et al. 1995).  The use of Brodmann’s numbering system 
became well established when it was used in conjunction with stereotaxic atlases for 
labeling specific structure locations in space; the additional introduction of functional 





Figure 1.1: Human Brain Anatomy. Lateral (A) and medial surface (B) of a human cerebral 
hemisphere and gyri patterning for lobe identification.  Adapted from Gray’s Anatomy.   
 
 
Many early insights into cortical function came from medical observations of 
disease and injury.  Impaired function in cortical regions negatively impacts sensing, 
perceiving and interacting with the surrounding environment.  Confirmed at autopsy, 
in some of these medical cases damage to specific regions of the cortex provided 
neurologists with evidence linking their behavioral phenotype to brain damage.  
Similar lesions located during autopsy along two separate patients’ frontal gyri led 
Dr. Broca to link his observed phenotype of difficultly producing speech to a narrow 
region roughly corresponding to Brodmann’s area 44 nd 45.   Broca’s patients 
comprehended language and followed spoken directions, however could not speak.  





written words, and it was associated with damage to the superior temporal gyrus.  
Two well-known and classic examples further illustrate the importance of more 
complex cortical connectivity and function: Phineas Gage and an amnesiac case-study 
patient referred to as “H.M” (Henry Molaison).   
Mr. Gage survived a railway accident in which his left frontal lobe was 
severely damaged and second-hand accounts note significant behavioral changes after 
the traumatic injury.  He died in 1860, however his skull was recently imaged to 
further examine the extent of damage and the research rs reconsidered alterations of 
brain networks based on our current understanding of cortical connectivity (Van 
Horn, Irimia et al. 2012).   Recent animal and human studies have correlated damage 
to frontal cortices to impairments in executive function, decision making, and 
memory (Moore, Schettler et al. 2009; Kesner and Churchwell 2011; Stuss 2011).  
Even more important to the study of cortical and sub-cortical function came from the 
patient H.M., who underwent a bilateral medial temporal lobectomy in an attempt to 
prevent persistent epileptic seizures in the early 1950’s. Post-op he suffered profound 
memory impairment, specifically anterograde amnesia or nability to convert short 
term working memory into new long-lasting memories (Scoville and Milner 1957; 
Squire 2009).  H.M’s inability to retain information and to form new memories 
coupled with his relatively unimpaired memory for events that occurred before his 
lobectomy imply that the medial temporal lobe region is necessary to form new 
memories but old consolidated memories are not stored in the same location.    Dr. 
Milner’s findings regarding H.M. forced reevaluation regarding memory function and 





discriminating between types of memory and demonstrated the potential of multiple 
memory systems.   
Portions of cortex can also be broadly subdivided based on their function into 
sensory (auditory, visual and somatosensory) and motor (pre- and primary), while 
cortical regions involved in complex relationships (e.g. learning, emotion and 
attention) are termed associative and tend to have mor  inter-cortical connections.    
Associative regions within the frontal lobe mediate ex cutive function actions such as 
working memory, attention, decision making and task-oriented behaviors (Ofen, Kao 
et al. 2007; Axmacher, Schmitz et al. 2008).   Behavior l tasks such as the Wisconsin 
Card Sorting Task (Jodzio and Biechowska ; Nyhus and Barcelo 2009) and the Stroop 
Interference Test (Hyafil, Summerfield et al. 2009) illustrate intact executive function 
in humans.   Further evidence supporting frontal lobe mediation in executive 
functions comes from electrophysiology recordings in non-human primates showing 
activation of neurons within a specific context (Mansouri, Matsumoto et al. 2006; 
Zaksas and Pasternak 2006).  The temporal lobe contains auditory cortex (BA 41 and 
42) and processes sound, additionally the medial portion encapsulates the 
hippocampus and functions in declarative memory processing (Gour, Ranjeva et al. 
2011).  The hippocampus is integral to formation of ew memories regarding 
experience, detection of novel stimuli and spatial navigation (O'Keefe and Nadel 
1978; Driscoll and Sutherland 2005). 
Recent groundbreaking studies coupled with enhanced imaging technology 
and the ability to detect brain activity in normal individuals illustrates several relevant 





responsible for specific functions.   Memory involves multiple systems and is not 
compartmentalized to one region.  Injury and/or disease impact and cause specific 
impairments to sub-sets of function depending on locati n, e.g. short vs. long-term 
memory (Levy and Goldman-Rakic 1999; Marklund, Fransson et al. 2007). 
Brain Barriers and Fluids 
The brain depends on delivery of molecules, such as oxygen and glucose, 
from the peripheral blood supply; however transportation across the blood-brain 
barrier must be tightly regulated to maintain homeostasis.  Underneath the meninges a 
thin collection of glial processes connect to the basal lamina of the cerebral cortex to 
form the glial limitans and divides the central nervous system from the rest of the 
body.  Larger blood vessels penetrating the cerebrum pass through the subarachnoid 
space and are covered by a thin meningeal layer, th pia mater, which results in a 
perivascular space and serves as a drainage route for brain interstitial fluid.  
Astrocytes also support and provide signals to capillary endothelial cells to form tight 
junctions, which are essential for maintenance of the blood-brain barrier (Abbott, 
Ronnback et al. 2006).   These junctions along brain v sculature create the seal 
necessary for optimal operation of the blood-brain barrier, and along with the glia 
limitans and the perivascular space regulate fluid low in the central nervous system.    
Together these components separate blood from the interstitial space, carefully 
policing the movement of molecules from the periphery and serving to protect the 
brain and spinal cord from foreign substances.  
Produced in the choroid plexus from arterial blood, the cerebrospinal fluid 





Cerebrospinal fluid is continually made and reabsored into the blood and in addition 
to providing mechanical support it serves an important role in facilitating cerebral 
blood flow, movement of nutrients, and removal of waste through excretion to venous 
blood.  While brain interstitial fluid contacts neurons and glial cells directly, 
cerebrospinal fluid remains separate but mixes withbrain interstitial fluid and thus 
contributes to the local environment surrounding brain tissues.   Sampling the 
cerebrospinal fluid provides scientists with a closer view of the brain environment 
and examining the composition of cerebrospinal fluid provides useful information 
regarding health and neurological diseases.  Certain s imuli and chemical substances 
are capable of opening up the blood-brain barrier and excessive release of pro-
inflammatory cytokines can disrupt the blood-brain barrier during a neuro-immune 
response (Coisne and Engelhardt 2011).   
 
Alzheimer’s disease (AD) 
Introduction 
Exceptionally complex interactions between many levels and systems, both 
inside and outside the body, impact an organism’s life pan and contribute to a 
differential aging phenotype.   Alzheimer’s disease (AD) is an age-related progressive 
neurological form of dementia.  First described as presenile degeneration by Dr. Alois 
Alzheiemer in 1906, major characteristics of AD include behavioral and cognitive 
problems such as degeneration of memory and changes i  p rsonality that affect the 
ability of a person to carry out daily activities.  AD patients exhibit profound memory 





changes and eventual failure to communicate with friends and family.  According to 
the Alzheimer’s Association one in 10 people over th  age of 65 and close to half 
over the age of 85 have AD.  The ADAMS report (Plassman, Langa et al. 2007) 
indicates in America alone, nearly 2.5 million dementia patients over the age 71 have 
Alzheimer’s disease.  Annual cost for care for patients with AD exceeds billions of 
dollars and excessive stress takes its toll on caregivers. 
Researchers cannot yet pinpoint specific causes of the disease, because the 
etiology of AD is still poorly understood.  Currently a multitude of factors including 
sex, race, socioeconomic status, and education are assessed in order to determine an 
overall risk for the disease.  Professionals agree (ADEAR 2007) that the development 
of AD is the result of a complicated course of both genetic and non-genetic factors, 
with increasing age being the biggest determining aspect.  Even with advancing 
scientific tools and technologies, a medical diagnosis f AD is usually based on 
criteria outlined in the 4th edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV, (APA 2000) and neuropsychological evaluation using the Mini-
Mental State Examination (MMSE).  The patient must exhibit impaired memory 
along with at least one of the following conditions: problems with executive function, 
aphasia, apraxia or agnosia.  According to the critria, these cognitive impairments 
occur gradually and continue over time interfering with occupational functioning and 
social interaction.  According to the National Institute of Neurological and 
Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ARDA) rating scale, established in 1984, a definite AD 





Feldman et al. 2007).  This analysis utilizes Braak st ging of I – VI; stage I denotes 
the earliest stage of pathology located around the entorhinal cortex and stage VI 
represents spreading of pathology throughout the neocortex into the occipital lobe 
(Braak and Braak 1991; Braak, Thal et al. 2011).  However, recently the National 
Institute on Aging (NIA) and Alzheimer’s Association proposed new guidelines for a 
medical diagnosis of AD and incorporates criteria for stages of disease progression 
along with utilization of biomarker tests (Jack, Albert et al. 2011)  
An estimated 5% of AD cases are early onset (Alzheimer's Association 2008); 
affecting people aged 30-65.  Early onset AD seems to follow a rigorous pattern of 
inheritance and is often referred to as familial AD.  Cases have been linked to 
mutations of the amyloid precursor protein (APP) gene on chromosome 21, mutations 
that impact functioning of γ-secretase in the presenilin 1 (PSEN-1) gene located on 
chromosome 15 or  a similar gene called presenilin 2 (PSEN-2) on chromosome 1 
(McClearn and Vogler 2001; ADEAR 2007).  Remaining cases of AD are late onset 
and idiopathic, with no clear pattern in onset or severity of disease pathology.  A 
widely recognized genetic risk factor in late onset AD is a particular form of the 
apolipoprotein E (ApoE) gene on chromosome 19.  Inheritance of one or two copies 
of the ε4 allele increases risk for idiopathic AD (McClearn d Vogler 2001; Serretti, 
Olgiati et al. 2007).  However, presence of this allele does not predict whether or not 
a person will develop AD.  While the mechanisms are not clearly understood, 
different ApoE isoforms preferentially bind Aβ peptides and that affinity may 
contribute to the higher risk of ε4 carriers in developing AD due to reduced clearance 





southern Italy reports a protective effect of the ApoE ε2 allele in familial AD and 
idiopathic AD due to more efficient action of the isoform (Panza, Solfrizzi et al. 
2000; Rebeck, Kindy et al. 2002), while others suggest that ApoE ε2 improves 
cognition in the oldest old but does not reduce accumulation of Alzheimer’s 
pathology (Berlau, Corrada et al. 2009). Other contribu ing factors linked to 
idiopathic AD include cardiovascular disease, type II diabetes, oxidative damage and 
inflammation, and traumatic brain injury (Weller, Yow et al. 2002; Mahley, 
Weisgraber et al. 2009; Johnson, Stewart et al. 2010; Bosco, Fava et al. 2011) 
Irrespective of type, the major pathological characteristics of AD are very 
similar and include abnormal protein aggregation, neuronal loss, brain shrinkage, and 
cognitive decline.  More specifically the development and deposition of amyloid-β 
plaques in brain parenchyma and cerebral vessels (angiopathy) along with 
neurofibrillary tangles containing aggregates of hyperphosphorylated tau occurs with 
advancing age.   Several studies have documented and reviewed neuronal losses in 
Alzheimer’s relevant regions including basal forebrain, hippocampus, cortex and 
locus coeruleus (Zarow, Lyness et al. 2003; Chetelat, Villemagne et al. 2010; 
Brunnstrom, Friberg et al. 2011; Schliebs and Arendt 2011).  Additional magnetic 
resonance imaging (MRI) studies reveal alterations n brain volume and have 
identified other key locations such as cingulate cortex (Jones, Barnes et al. 2006; 
Amanzio, Torta et al. 2011).   Aberrant microglial activation and astrocyte pathology 
correspond to elevated pro-inflammatory processes and changes in permeability of 
the blood-brain-barrier (Li, Zhao et al. 2011; Crehan, Hardy et al. 2012).  Cell culture 





reduced integrity of the blood-brain barrier (Nishit uji, Hosono et al. 2011).  These 
combinations of factors directly impact brain regions important for memory processes 
and lead to the varied symptoms experienced by AD patients.   
Alzheimer’s pathology 
Biochemical alterations lead to cortical atrophy and poptosis leading to 
enlargement of brain ventricles and cortical thinning.  Coupled with neuronal loss in 
the basal forebrain and hippocampus (Zarow, Vinters et al. 2005), overall shrinkage 
of brain tissue impacts memory recall and formation of ew memories.  Plaques 
containing Aβ form due to irregular amyloid precursor protein processing (Hardy and 
Allsop 1991; Selkoe 2000; Tseng, Kitazawa et al. 2004), accumulation ultimately 
results in degeneration of axons and dendrites.   Dysfunctions in microtubule 
associated protein tau lead to neurofibrillary tangles inside the cell body (LaFerla and 
Oddo 2005; Gendron and Petrucelli 2009), impairing neuronal stabilization and 
contributing to neuronal loss.   
In the central nervous system, acetylcholine functions as the major 
neurotransmitter of the basal forebrain cholinergic system.  Acetylcholine enhances 
hippocampal and cortical processing; contributing to arousal, maintaining attention, 
learning and preserving memory (Hasselmo and Giocom 2006; Roberts and Thiele 
2008; Klinkenberg, Sambeth et al. 2011).  Early studies of AD reported significant 
decreases in synthesis and release of acetylcholine, which was linked to neuronal loss 
in the basal forebrain and dementia (Whitehouse, Price et al. 1982; Coyle, Price et al. 
1983).  Researchers proposed that the cognitive decline in AD was due to cholinergic 





formed the basis for one of the oldest AD hypotheses.  This hypothesis focused 
attention on the basal forebrain and proposed the loss of acetylcholine in the central 
nervous system as the central pathological feature for development of AD.  
Deterioration of memory and cognitive abilities occurs due to degeneration of 
cerebral presynaptic cholinergic neurons and resulting imbalance in acetylcholine 
metabolism (Smith and Swash 1978; Bartus, Dean et al. 1982).  Reversible inhibition 
of acetylcholine causes memory impairment in animal odels and application of an 
acetylcholinesterase inhibitor reverses cognitive deficits (Arendt, Schugens et al. 
1990; Van Dam, Abramowski et al. 2005).   Based on these sorts of studies, 
acetylcholinesterase inhibitors were developed for pharmacological interventions and 
the majority of Food and Drug Administration approved drugs in use to treat AD 
target the acetylcholine system.  These drugs inhibit t e breakdown of acetylcholine, 
leading to an increase in the brain and making it avail ble for re-release at the 
synapse.  Support for this hypothesis declined due to an overall lack of effectiveness 
in AD patients to sufficiently restore acetylcholine, nor do these drugs significantly 
reduce amyloid burden or improve cognitive status long term.    
A hallmark feature of AD is the deposition of amyloid-β plaques first 
developing in areas of the brain relating to memory. It is a protein fragment cleaved 
from a larger complex called amyloid precursor protein.  This protein contains 
enzymatic cleavage sites for α-, β-and γ-secretase (Figure 1.2) resulting in two major 
cleavage pathways.  Cleavage of amyloid precursor protein and activity in the 
presenilin family (PS1/PS2) influences γ- ecretase and leads to the generation of 





function of amyloid precursor protein in neuronal development and regulation of 
synaptic plasticity (Priller, Bauer et al. 2006) and i  normal healthy neurons α-
secretase cleavage predominates to form non-pathogenic p ptides.   The pathogenic 
pathway characterized by cleavage of amyloid precursor protein by β-secretase 
instead of α-secretase results in generation of distinct pathogenic amyloid-β peptide 
isoforms (Hardy and Selkoe 2002).  In AD there is ashift in processing to slightly 
longer protein 42 amino acids in length, forming amyloid beta-42.  Amyloid-β42 
aggregates with other amyloid fragments to form deposits (Lorenzo, Yuan et al. 2000; 
Selkoe 2000).  Compared to the Amyloid-β40 isoform, Amyloid-β42 aggregates more 
readily and is more cytotoxic (Chen and Glabe 2006; Jan, Gokce et al. 2008; 
Hedskog, Petersen et al. 2010; Kuperstein, Broersen et al. 2010).  Another factor in 
progression of AD pathology is the ratio of amyloid-β42:amyloid-β40 (Lewczuk, 
Esselmann et al. 2004; Wiltfang, Esselmann et al. 2007).  Conversion from 
monomeric amyloid peptides into oligomeric amyloid deposits contribute to neuronal 
loss resulting in memory deterioration and observable cognitive deficits.  Under 
normal functioning circumstances amyloid-β is catabolized and cleared by 
endogenous mechanisms; however, in AD it accumulates extracellularly and 
intraneuronally (Oddo, Caccamo et al. 2006).  Recently it has also been reported that 
soluble Aβ fractions, including monomers and oligomers, correlate better to cognitive 
impairment (Tomic, Pensalfini et al. 2009) and soluble fractions impair synaptic 







Figure 1.2: Amyloid Precursor Protein. Liberation of amyloid-β peptide fragment via sequential 
secretase cleavage of the full length protein.  
 
 
The discovery that amyloid was the main component of these deposits led to 
the belief that the progressive buildup of Aβ in the brain caused AD.  Proponents of 
the amyloid hypothesis (Hardy and Allsop 1991; Hardy and Higgins 1992; Coria, 
Rubio et al. 1994) believe amyloid precursor protein processing and the formation of 
plaques to be the key events in development of AD. Changes in amyloid-β 
metabolism then lead to the downstream changes: (1) increased formation of 
pathogenic amyloid isoforms (2) microglia and astrocyte activation (3) neuronal loss 
(4) senile plaque and tangle pathology.  Many support this hypothesis because 
amyloid-β accumulates and forms aggregated deposits prior to other definable 
symptoms of AD.  While APP/PS1 mutations in familial AD could account for the 
initial generation of amyloid-β this hypothesis does not adequately explain the trigge  
in idiopathic AD; in humans plaques also increase with aging and a relatively high 
amyloid burden present in only mild cases of cognitive impairment or even in 
cognitively normal subjects suggest that other mechanisms should be considered.     
The last major feature of AD relates to the cytoskeleton protein tau and tangle 
formation.  Tau plays an important role in cellular trafficking, organizing and 





hyperphosphorylated form it cannot bind microtubules.  Instead tau aggregates into 
twisted protein and accumulates in nerve cell bodies, forming tangles.  It is generally 
thought that neurofibrillary tangles disrupt axonal tr nsport eventually leading to 
neuronal death.  Advocates for a tau hypothesis of AD (Goedert, Spillantini et al. 
1992; Strittmatter, Weisgraber et al. 1994; Schmitz, Rutten et al. 2004) assign the 
major causative role to neurofibrillary tangles; compared to the amyloid cascade 
hypothesis where the influence of tau occurs downstream of amyloid aggregation.   
Disrupted axonal transport impairs the ability of neurons to properly export proteins 
to distal regions or receive trophic factors at terminals compromising survivability of 
neurons with accumulating NFTs (Trojanowski and Lee2005) and thus contributing 
to the pathology of AD independently of amyloid.  Other support for this angle comes 
from studies indicating that amyloid load does not correlate with cognitive decline or 
neuronal loss (Schmitz, Rutten et al. 2004).   However, on their own, tau mutations 
do not lead to significant production of amyloid pathology.   
Modeling AD 
Experimental animal models provide precise control over experimental 
manipulations allowing researchers to minimize extraneous noise in data collection.  
Shorter lifespans are also appealing, allowing for easier repetition and larger sample 
sizes for studies.  Essential tools in translating our understanding into medical 
advances in the study of disease include integrative pproaches using animal models.  
Animal models of AD include transgenic mice expressing selected atypical human 





targeting specific neurotransmitter systems thought to be involved in the development 
of AD. 
Transgenic animal models only relate to a small propo tion of AD cases due 
to gene mutations.  While similar challenges to human studies exist, experiments with 
non-human primates can be carefully controlled and monitored throughout their time 
course.  Humans and non-human primates share significant physiological aspects and 
they develop amyloid pathology naturally with age.  Currently no animal exists for 
late onset AD, this idiopathic form accounts for approximately 95% of reported cases. 
Alzheimer’s disease greatly impacts the lives of patients and caregivers.  
Complicated patient history and compliance issues ar  two important factors 
impacting a researchers control over the experiment alo g with scope of inference in 
studies with human subjects; experiments require extremely large sample sizes in 
order to draw meaningful conclusions from the data.  Additionally, in studies with 
humans, obtaining optimally prepared tissue samples can be difficult and time 
consuming given their extended lifespans.   
Neuroinflammation 
Introduction 
An inflammatory response is an early immune reaction to trauma or invading 
pathogens; in the central nervous system microglia act as the resident immune system 
and mediate neuroinflammatory processes (Streit, Mrak et al. 2004).  Activation of 
microglia and increased cytokine production characterize immune responses in the 
brain.  Under normal circumstances microglia exhibit a resting (ramified) phenotype, 





microglia sense a change in the environment, they respond by a shift in phenotype 
and become activated.  These activated microglia migrate and proliferate at the site of 
trauma.  They communicate with astrocytes and releas  ffector molecules to deal 
with the insult; released cytokines may be beneficial or detrimental, often depending 
on the period of time microglia remain activated.   Therefore, in terms of pathology, it 
is important to distinguish between acute and chronic neuroinflammation. 
Cytokines 
Cytokines are central to immune responses in the brain and regulate 
inflammatory pathways.  Different families of cytokines are involved in pro- or anti-
inflammatory mechanisms and released by glial cells.  Interleukin-1β, interleukin -6, 
and tumor necrosis factor- α are all expressed during pro-inflammatory actions, while 
interleukin -10 family cytokines are considered anti-i flammatory.  During an 
inflammatory response, microglia and astrocytes release cytokines in response to 
trauma.  The production of these different families of cytokines regulates both the 
strength and length of an immune response (Tuppo and Arias 2005). 
Relationship to AD 
Activated microglia are thought to play a role in development of age-related 
inflammatory diseases and have also been shown to increase during aging in non-
human primates (Sheffield and Berman 1998).  Alzheimer’s disease has been 
associated with chronic microglia activation and morph logical changes leading to 





may further accentuate the neurotoxic response.  In rodents, these alterations impact 
the integrity of surrounding neurons often exacerbating disease conditions. 
Oxidative stress and neuroinflammation play critical roles in the pathogenesis 
of AD due to interactions between astrocytes, microglia and AD pathology within the 
inflammatory response.  Further study of free radicls has shown that they promote 
amyloid aggregation.  This interaction of β-amyloid and reactive oxygen species 
(ROS) may enhance damage to brain tissue resulting in the increasing neuronal 
damage seen in AD.  Dead and damaged neurons promote i mune responses 
triggering activation of microglia which respond at the injured locations to scavenge 
debris and remove it.  However, when microglia remain in their activated state for a 
sustained period of time they also release harmful pro-inflammatory cytokines which 
promote chronic neuroinflammation and contribute to neuronal death.  The amyloid-β 
protein sustains microglia activation and leads to increased secretion of cytokines that 
impact neuronal viability (Barger and Harmon 1997; Barger and Basile 2001; 
Sondag, Dhawan et al. 2009).   
Several cytokines are relevant to AD and have been m asured in areas 
surrounding amyloid-β plaques, notably the interleukins and tumor necrosis factor-α.   
A cycle of activation, initiated microglial release of interleukin-1 and production of 
interleukin-6 in in astrocytes, enhances further activ tion and production of cytokines.  
In this way interleukin-6 promotes neuroinflammation and astrogliosis.  High levels 
of tumor necrosis factor-α released from microglia contribute to neurotoxic activation 
and indicate ongoing inflammation. Cell culture expriments show dramatic increases 







In the periphery, norepinephrine is synthesized and released from chromaffin 
granules in the adrenal gland into the blood stream where it acts as a hormone via the 
endocrine system.  Results of increased norepinephrine from sympathetic neurons in 
the periphery are increased cardiac muscle contractions and enhanced blood flow to 
muscles during the flight-or-flight responses.  The locus coeruleus is a small midbrain 
structure contained in the pons and is responsible for norepinephrine release in the 
central nervous system (Figure 1.3).  The locus coeruleus contains a dense cluster of 
neuronal cell bodies that synthesize norepinephrine and fibers project to regions of 
the brain that utilize norepinephrine as a neurotransmitter, e.g the hippocampus and 
prefrontal cortex (Thompson 2000; Sharma, Xu et al. 2010).   
Locus coeruleus neuronal firing patterns change dramatically when an animal 
is awake versus sleeping, suggesting that this system contributes to wakefulness 
(Devilbiss, Page et al. 2006) and altering electrical stimulation patterns in the locus 
coeruleus impacts norepinephrine release in projecti n regions (Florin-Lechner, 
Druhan et al. 1996).  Furthermore, these neurons display burst firing patterns in 
response to behavioral sensory stimuli and activation of the locus coeruleus is 
associated with detecting salience, an important mechanism for focusing attention 
which facilitates learning (Aston-Jones, Rajkowski et al. 1999; Bouret and Sara 
2004).  A functional role for the locus coeruleus in decision making and memory 
processing has been proposed (Aston-Jones, Rajkowski et al. 2000; Rajkowski, 





activation of locus coeruleus neurons during behavior l tasks which require a change 





Figure 1.3: Location and projections from Locus Coeruleus. Brain schematic illustrates projections 
of dopamine from the Substantia Nigra (blue arrows) and norepinephrine (green arrows) from the 
Locus Coeruleus. Mid-sagittal view. 
 
Synthesis, Degradation and Regulation 
Dopamine and norepinephrine are prevalent neurotransmitters in both the 
central and peripheral nervous system.  The initial building block for these 
catecholamines, tyrosine, is an amino acid acquired from protein food sources and 
can be synthesized in the body from phenylalanine.  Tyrosine is converted into L-
dopa by the enzyme tyrosine hydroxylase, which is in turn converted into dopamine 





hydroxylase changes dopamine into norepinephrine (Figure 1.4).  Tyrosine 
hydroxylase is present in all catecholamine-producing neurons and therefore 
considered to be a general marker of catecholamine neurons.  Dopamine β-
hydroxylase, which is present within vesicles of cells producing norepinephrine, 
specifically labels noradrenergic neurons.   Due to its small densely packed 
morphology and more isolated location within the midbrain, both enzymes have been 





Figure 1.4: Synthesis pathway for dopamine and norepinephrine. Synthesis occurs via DOPA 
decarboxylase and dopamine-β-hydroxylase (A).  Monoamine Oxidase and Catechol-O-methyl 
transferase are the main steps in norepinephrine degra ation, resulting in formation of two amine 
metabolites: 3-methoxy-4-hydroxy-phenylethylglycol and vanillylmandelic acid (B). 
 
Noradrenergic receptors on post-synaptic terminals i  locus coeruleus 
projection regions contain two major types of adrene gic receptors, generally 










































receptors typically leads to excitation; while α2-receptors on post-synaptic 
membranes lead to inhibition and α2-receptors on presynaptic membranes provide 
autoregulation inhibiting locus coeruleus activity via negative feedback.  Downstream 
transduction of α1-receptor activation proceeds through Phospholipase-C resulting in 
elevated Ca+2; whereas, stimulation of α2-receptors inhibits adenylate cyclase and 
reduced excitability decreases neurotransmitter relase.  Stimulation of β-receptors 
impacts protein kinase A phosphorylation cascades and enhances long term 
potentiation.  Obvious complexities arise as regional differences in norepinephrine 
action occur due to varying receptor distributions a d norepinephrine concentration. 
 After signaling, norepinephrine degradation occurs th ough monoamine 
oxidase or reuptake occurs through two main transporters: Norepinephrine transporter 
from the synaptic cleft and vesicular monoamine transporter inside the terminal.  In 
addition to synthesis, autoregulation and reuptake impact the availability of 
norepinephrine.   The most common metabolite of norepinephrine, 3-methoxy-4-
hydroxyphenylglycol, can be measured in cerebrospinal fluid and used as a general 
marker for norepinephrine turnover. 
Pathology  
Deficits in other neurotransmitter systems have also been documented in 
aging and neurodegenerative disease, although the clinical significance of the locus 
coeruleus-norepinephrine system in AD is not well understood.  Early research 
describes decreases of norepinephrine in the hindbrain with age along with increase in 
monoamine oxidase-B, the enzyme responsible for degra ing norepinephrine 





described (Wilcock, Esiri et al. 1988) and others have documented losses of 
norepinephrine in locus coeruleus projection areas along with alterations in amine 
metabolites (Adolfsson, Gottfries et al. 1979).    
After trauma, plasticity related changes such as increased tyrosine 
hydroxylase mRNA expression, dendritic sprouting, and ltered receptor expression 
in hippocampus has been associated with reduction of locus coeruleus neurons.  The 
amount of tyrosine hydroxylase in a neuron is important because it is the rate limiting 
step for the synthesis of both dopamine and norepinephrine.  Even with a loss of 
norepinephrine neurons, reports of increased activity in surviving neurons (Szot, 
White et al. 2006) indicate that the brain may be al  to compensate for some amount 
of time.    
Two types of axon terminals releasing norepinephrine have been described, a 
conventional terminal with classic norepinephrine neurotransmitter release to activate 
adrenergic receptors and release of norepinephrine from extra-synaptic varicosities to 
diffuse into the microenvironment to act on glial ce ls and other neurons (Marien, 
Colpaert et al. 2004).   Norepinephrine suppresses inflammatory gene expression 
(Feinstein, Heneka et al. 2002) and reduces expression of inflammatory proteins 
(Frohman, Vayuvegula et al. 1988); significant decreases in norepinephrine could 
then contribute to elevated cytokine production from activated microglia and 
apoptosis signaling molecules leading to further neuroinflammation and neuronal 





N-(2-bromobenzyl)-N-(2-chloroethyl) ethylamine hydrochloride (DSP-4) 
 Prior to discovery and use of neurotoxins, scientists studied nerve function 
and resultant physiological perturbations following physical damage to nerves and/or 
transection of axons.   However, this type of approach is not as practical in the brain 
because nerve bundles are difficult to isolate from one another or the target brain 
regions may not be easily accessible.  Furthermore, mechanical or electrolytic lesions 
are nonspecific and often result in damage outside the target.  Neurotoxins can be 
administered to produce site specific lesions of neurotransmitter systems in the brain.  
The discovery of various toxins and their effects ha allowed for extensive study of 
morphology, biochemistry and physiology in specific brain systems.  This approach 
provides a more precise experimental method to study the function of particular 
neurotransmitters and to model certain disease pathologies.   
  The noradrenergic neurotoxin DSP-4, originally described by Ross & 
colleagues in 1973, crosses the blood brain barrier and is converted to an aziridinium 
ion to exert neurotoxic effects in the locus coerulus leading to depletion of 
norepinephrine.   Ross and Renyl’s original experimnts demonstrated that DSP-4 
blocked norepinephrine uptake in brain slices and further that the effect they reported 
was specific to norepinephrine, suggesting that DSP4 interacted with a 
norepinephrine-specific transport mechanism into the neuron.  Using their slice 
culture model, they described a long lasting  impairment of norepinephrine uptake up 
to 4 weeks after a single dose of 100 mg/kg and doses f 25mg/kg and 50 mg/kg 





 The precise mechanism by which DSP-4 exerts cytotoxic denervation is not 
well understood, however effects are duplicated by the highly reactive aziridinium ion 
form.   The neurotoxin must be prepared and injected quickly prior to this 
spontaneous reaction because the ionic form does not cross the blood brain barrier 
(Zieher and Jaim-Etcheverry 1980).  The negative eff cts of DSP4 can be mitigated 
by pre-treatment with desipramine, a norepinephrine t ansport blocker, suggesting 
that the transporter is required for the neurotoxic effects of DSP4.  
Experimentally induced locus coeruleus lesions in AD-transgenic models 
produce elevated amyloid and induce inflammation (Kalinin, Gavrilyuk et al. 2007).   
Reported locus coeruleus degeneration in cases of mild cognitive impairment, often 
considered a pre-AD stage, suggests that locus coeruleus dysfunction occurs early on 
prior to more significant amyloid deposition (Grudzien, Shaw et al. 2007).   
Studies with non-human primates 
Amyloid 
Long-lived animal models with naturally developing amyloid are necessary in 
order to better understand effects of deposition and aggregation of amyloid on brain 
function.  The common squirrel monkey (Saimiri sciureus), a small new world 
primate, shows more vascular amyloid deposition of amyloid (Walker, Masters et al. 
1990; Elfenbein, Rosen et al. 2007); while more parenchymal deposition occurs in 
senile plaques of the rhesus macaque (Macaca mulatta), a larger old world monkey 
(Wei, Walker et al. 1996; Shah, Lal et al. 2010).   Both amyloid precursor protein 
processing pathways occur in non-human primates (Podlisny, Tolan et al. 1991) and 





deposits present as both diffuse and compact morphologies, containing both Aβ40 
and Aβ42 (Kanemaru, Iwatsubo et al. 1996; Hartig, Goldhammer et al. 2010).  
However, the amount and isoform distribution varies d pending on species, and 
similar to humans large variation is noted among individuals of similar age.  
Rationale: Locus Coeruleus, Norepinephrine and AD  
Degeneration in the locus coeruleus is a documented feature of AD; however its role 
remains unclear (Bondareff, Mountjoy et al. 1987; Burke, Chung et al. 1988; Marien, 
Colpaert et al. 2004).  The DSP-4 model will provide a means to further investigate 
the role of norepinephrine depletion prior to onset of AD pathology using two species 
of non-human primates.  This approach is ideal because while mice have a much 
shorter lifespan and are easily manipulated genetically, they do not develop AD 
pathology in an idiopathic manner.  Non-human primates develop amyloid pathology 
naturally (Walker, Masters et al. 1990; Podlisny, Tolan et al. 1991) and the rhesus 
monkey genome is 93% similar to humans (Gibbs, Rogers et al. 2007).  Currently no 
animal model exists for idiopathic AD, which accounts for the vast majority of all 
human cases.  Development of idiopathic model AD would provide a new valuable 
model for exploring novel therapeutics and interventions designed to slow down 
pathogenesis, ultimately lessening costly health consequences.    
Hypothesis and predictions 
 
Age is the largest risk factor for development of AD pathology and degeneration in 
locus coeruleus has been documented in cases of AD.  Norepinephrine deficiency 





amyloid pathology and neuroinflammation will increas  with age.  Pharmacological 
reduction of norepinephrine with DSP4 will be permissive for pathology development 
resulting in onset and increased accumulation of Alzheimer’s pathology, chronic 





Chapter 2: Increased Amyloid pathology in non-human primates 
following DSP-4 injection resulting in impaired locus coeruleus 
function  
Introduction 
Alzheimer’s disease (AD) affects 5.4 million Americans and the World Health 
Organization estimates 18 million people worldwide; without successful intervention 
the number of AD patients could easily triple by 2050, considering longer life 
expectancies and the aging baby boomer population (Alzheimer's-Association 2012).  
This progressive neurological disease impairs cognitive and executive functions, 
including severe impairments of memory and attention.  Cognitive and sensory neural 
systems seem preferentially impacted by AD with amyloid plaque accumulation, 
hyperphosphorylated tau formation, neuroinflammation, and neuronal loss.  
Biochemical alterations and deposition of pathology begin well before behavioral 
symptoms and the onset of dementia. 
 One widely supported hypothesis of AD highlights amyloid as the central 
player in disease progression, with focused attention on generation and deposition of 
amyloid-β with subsequent plaque formation (Hardy and Allsop 1991; Hardy and 
Selkoe 2002).  More recently, the primary hypothesis has shifted to focus on the 
importance of soluble amyloid isoforms and their contribution to AD pathology and 
cognitive decline (Selkoe 2008).  Formation of amyloid-β occurs via a proteolytic 
cleavage pathway in which amyloid precursor protein forms isoforms based on the 
site specific cleavage by β- and γ-secretase.  These peptides also undergo post-
translational modifications which impact the solubiity, aggregation and degradation 





from clinical AD cases primarily contain aggregates of Aβ-40 and Aβ-42, while 
vascular deposits are made up of mainly Aβ-40.   Soluble monomers of these peptides 
form larger oligomers, which have been shown to interfere with synaptic function and 
have the potential to disrupt neurotransmission including long term potentiation 
(Walsh, Klyubin et al. 2002; Selkoe 2008). 
The locus coeruleus contains the highest density of noradrenergic system cell 
bodies that synthesize and distribute norepinephrine to wide-ranging brain regions, 
including neocortex and hippocampus.   Locus coeruleus degeneration and 
norepinephrine loss are also well documented featurs of AD (Mann and Yates 1981; 
Mann, Yates et al. 1982; German, Manaye et al. 1992) along with other types of 
dementia (Zarow, Lyness et al. 2003; Brunnstrom, Friberg et al. 2011) and aging 
(Manaye, McIntire et al. 1995); although other reports suggest similar neuronal 
counts in adult and non-demented aged cases (Mouton, Pakkenberg et al. 1994; Ohm, 
Busch et al. 1997). Changes in norepinephrine transporter and adrenergic receptor 
subtypes are associated with locus coeruleus impairent; both contribute to reduced 
norepinephrine in projection regions and likely contribute to bio-psychiatric 
symptoms observed in AD patients (Tejani-Butt, Yang et al. 1993; Matthews, Chen et 
al. 2002).  Demonstration of neuronal loss in the locus coeruleus actually exceeding 
cholinergic loss increased attention on the involvement of the locus coeruleus-
norepinephrine dysfunction in developing AD (Zarow, Lyness et al. 2003).  
 Several studies utilizing various transgenic AD mouse models expressing APP 
mutations further supported the hypothesis of norepinephrine involvement in AD 





noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) 
increased Aβ pathology (Heneka, Ramanathan et al. 2006; Kalinin, Gavrilyuk et al. 
2007; Jardanhazi-Kurutz, Kummer et al. 2010).  These early studies also reported 
increased astrocyte and microglia expression, induction of inflammatory pathways, 
and cognitive deficits following targeted locus coerul us degeneration in AD models 
(Heneka, Galea et al. 2002).  These findings suggested that locus coeruleus 
impairment and norepinephrine depletion was permissive for neuroinflammation.  
Further research confirmed suppression of both proinflammatory gene expression and 
cytokine production in microglia by norepinephrine; whereby induced degeneration 
by DSP4 increased secretion of these markers from microglia cells and impaired 
beneficial actions including phagocytosis (Heneka, N drigny et al. 2010).   
 Relating specific genetic mutations in APP to development of early onset AD 
provides important insights into disease progression. Studies with transgenic models 
continue to further understanding of aberrant disease pathways and are important for 
unraveling the complexities of AD; however their significance in fully 
comprehending idiopathic AD processes may not be adequate.   Many studies using 
AD transgenic murine models have examined the deposition of cerebral amyloid in 
parenchymal and vascular tissue.  However, this differs in non-human primates in 
which age related increases occur in aggregated amyloid similarly to humans; 
although deposition patterns vary between species (Uno and Walker 1993; Gearing, 
Tigges et al. 1996; Bons, Rieger et al. 2006).  Unoa d colleagues (1996) examined 
brains from 81 rhesus macaques (16-39 yrs) and 25/41 (21%) animals between the 





angiopathy.   In comparison, cortical cerebral amyloid angiopathy deposition was 
considerably higher than amyloid-β plaque formation in squirrel monkeys (Elfenbein, 
Rosen et al. 2007).  Non-human primates develop amyloid pathology naturally 
(Walker, Masters et al. 1990; Podlisny, Tolan et al. 1991).  The appearance of plaques 
and development of cerebral amyloid angiopathy is similar to observations from AD 
patients (Selkoe, Bell et al. 1987).  APP695 is predominantly expressed in neuronal 
cells and homology between the human sequence of amyloid precursor protein and 
both cynomolgus monkey and squirrel monkey is nearly identical (Selkoe 1991; 
Levy, Amorim et al. 1995).   
Few studies have investigated locus coeruleus-norepinephrine systems and 
their role in amyloid deposition using an animal model with natural age-related 
accumulation.  Thus non-human primates provide an opportunity to examine 
idiopathic development of early stage Alzheimer’s-like pathology following depletion 
of norepinephrine.  The aim of this study was to determine if DSP4 could induce and 
increase cerebral amyloid pathology in two species of non-human primates which 





Materials and Methods 
Subjects 
Pilot study: 3 female adult common squirrel monkeys (Saimiri sciureus, aged 
15 years) and 3 female adult rhesus monkeys (Macacca mulatta, aged 15-16 yrs) 
were studied in an initial short-term study (Table 1).  Long term study: 8 adult (11 
years old) and 5 aged (19-20 years old) squirrel monkeys were studied.    
Additionally, 14 adult (14-17 years old) and 7 aged (19-25 years old) rhesus monkeys 
were studied (Table 1).  All monkeys were female. 
Animals were obtained from approved sources and maintained at the National 
Institute on Aging/NIH primate facility prior to the study.  Animals were housed in 
standard non-human primate caging  and kept on 12:12hr light cycle, had ad libitum 
access to water and were fed standard NIH diet twice daily approximating ad libitum 
levels.  Animals were observed daily by trained observers, including checks on food 
consumption and well-being.  Routine health monitoring, TB tests and blood 
collections were done quarterly.   
Animal husbandry and all experimental procedures in the study complied with 
the National Institutes of Health Guide for the Care nd Use of Laboratory Animals 
and were conducted under an approved protocol by the NIA Institutional Animal Care 
and Use Committee (IACUC).  In addition, an IACUC protocol was also approved at 
the University of Maryland for all experiments utilizing non-human primate tissue 







Table 2.1: Animal Distribution and Treatment Groups.  All animals were housed at the National 
Institute on Aging (NIA) primate facility.  
 
 
*One adult squirrel and one aged rhesus animal died before the end of study 
 
Experimental Design 
Previous work with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) 
in several other species consistently reported norepinephrine depletion with a dose of 
50 mg/kg (Heneka, Ramanathan et al. 2006; Waterman and Harding 2008).   To 
confirm the utility and dosage of the DSP4 neurotoxin in non-human primates, 2 
control animals received vehicle and 4 adults received a single injection of DSP4 (50 
mg/kg); all animals were necropsied 30 days post injection.  
In the long term study (Figure 2.1), 4 adult and 3 aged squirrel monkeys 
received three injections of DSP-4 spaced 3 months apart (n=7), along with a control 
group receiving saline vehicle (n=6, Table 2.1).  To minimize transient peripheral 
side effects the dose used in the long term study was lowered to 40 mg/kg for the 
initial dose and 10 mg/kg for subsequent dosing.  Six adult and four aged rhesus 
monkeys received three injections of DSP4 spaced 3 months apart (n=10), along with 
Species Age Group Study Treatment n 








20 Aged Con 2 
11 Adult DSP-4 4* 










19-25 Aged Con 3 
14-17 Adult DSP-4 6 





a control group receiving saline vehicle (n=8, Table 1).  To prevent incidental 
serotonergic depletion each animal received an intraperitoneal (i.p.) injection of 
Zimelidine (Sigma: 10 mg/kg).  The initial DSP-4 dose (Sigma: 40 mg/kg, i.p.) was 
administered 45 minutes later.  Subsequent injections of Zimelidine followed by 
DSP-4 (10 mg/kg, i.p.) or vehicle were given at the 3 and 6 month time points. At 
each time point (baseline, 3, 6 and 9 months), before neurotoxin injection, blood was 
collected for serum analysis.  In the rhesus monkeys baseline behavioral testing was 
done prior to injections and then 1 month following each subsequent injection.  Three 
months after the final injections animals were necropsied.    
 
Figure 2.1: Long-term Study Design Squirrel and Rhesus monkeys were injected with DSP4 3 times 
over 9 months.  Behavioral testing (baseline and set-shift) was conducted with the rhesus monkeys 1 
month following injections. 
 
Tissue Collection 
Animals were restrained with ketamine and both blood and cerebrospinal fluid 
were collected.  Animals were deeply anesthetized using B-euthanasia-D (80 mg/kg, 
IV) and then perfused transcardially with cold 0.9% saline.  Brain tissue was prepared 
for biochemical and immunohistochemical assays.  Each brain was divided along the 
medial longitudinal fissure and blocked in 1 cm increments using an adult monkey 














isopentane and stored at -80°C for biochemical analyses; while the other hemisphere 
was immersion-fixed in 4% paraformaldehyde for 48 hrs, placed through a series of 
graded sucrose solutions until blocks sank in 30% sucrose and then frozen at -80°C.   
Enzyme Linked Immuno-Sorbet Assays (ELISAs) 
Tissue punches from specific brain regions were takn from fresh frozen 
tissue blocks for analysis of catecholamines and amyloid levels.  Punches for 
catecholamine measurements were homogenized (Fisher Scientific PowerGen125) in 
0.1N HCL, centrifuged (15k G) for 15 minutes at 4°C, and the supernatant was 
collected for ELISA.  Norepinephrine and dopamine were measured in prefrontal 
cortex (PF-C), caudate striatum (CS), hippocampus (HC), cingulate (CING-C), 
temporal cortex (TEM-C) and locus coeruleus (LC) using an ELISA specific to each 
catecholamine (Rocky Mountain Diagnostics, Inc. Colorado Springs CO) and run 
according to the manufacturer’s instructions.  All samples were run in duplicate.  
Absorbance values were determined using a microplate reader (BioRad 480) with a 
450nm filter.  The average optical density values for each region were interpolated on 
4-PL standard curves to determine catecholamine concentrations.  Catecholamine 
levels were standardized by sample protein levels masured using the BCA method 
(Pierce-Thermo Scientific, Rockford IL). 
Additional punches from prefrontal and temporal cortex were homogenized in 
5 volumes of homogenization buffer (50mM Tris-HCl, 150mM NaCl, with protease 
inhibitor cocktail) and then centrifuged at 100k g for 60 minutes at 4°C to generate a 
soluble fraction supernatant.  Amyloid-β40 and amyloid-β42 were measured in each 





instructions.  Samples were run in duplicate.  Absor ance values were determined 
using a microplate reader and a 540nm filter.  The average optical density values for 
each region were interpolated on 4-PL standard curves to determine catecholamine 
concentrations.  Levels were standardized for each s mple according to protein 
content.  
Immunohistochemistry (IHC) 
Fixed blocks were sectioned (50µm) on a freezing sta e sliding microtome 
and placed into cryopreservation buffer for storage t -20°C until immuno-histo-
chemical (IHC) staining.  Serial sections were collected from blocks throughout the 
brain to examine frontal cortex, hippocampus, pariet l, ntorhinal and temporal 
cortex.  Regions of interest were identified based on landmarks from a rhesus monkey 
stereotaxic atlas (Paxinos and Watson, 2009).  Subsets were stained with the 
following antibodies: Anti-Aβ 6E10 (1:1000, Covance, Emeryville, CA), Anti-DBH 
(1:1000 Millipore, Temecula CA) and Anti-Tau HT7 (1:500 Thermo Scientific, 
Rockford, IL). 
Stained sections were mounted onto PLUS slides and allowed to air dry for 3 
days. Slides were counter stained with cresyl violet and/or congo red, dehydrated, and 
then cover-slipped using permanent mounting medium. Slides dried for 1 week and 
were analyzed for amyloid subtypes in neocortex and norepinephrine containing cell 
bodies located in the locus coeruleus. 
Images were quantified using ImageJ (NIH) to analyze specific staining 
patterns for each antibody.  Thresholding was adjusted to isolate positively stained 





(Tynan, Naicker et al.).  The locus coeruleus region was imaged using a 4x objective; 
the %area was calculated and averaged on 2-3 serialctions per animal spaced 
100µm apart in the rhesus monkey and 50µm in the squirrel monkey.  Squirrel 
monkey 6E10-IR was determined on 2 serial sections spaced 500µm apart from each 
animal;  within each section three non-overlapping adjacent 10x images from each 
region of interest and %area stained was calculated.  Due to the rarity of 6E10-IR in 
rhesus monkeys under the age of 25 (Uno, Alsum et al. 1996) each observation of 
amyloid was counted using a 10x objective on two serial sections from frontal, 
entorhinal/temporal, and parietal regions.  Within each region instances of amyloid 
were summed for a regional count and then total neocortical load was determined by 
summing the counts from each region for each treatmn  group.   
Behavioral Measurements 
The rhesus monkeys used in this study were behaviorally naïve and first 
trained to respond/use a novel touchscreen apparatus.  The apparatus consisted of a 
touch sensitive computer screen and food pellet dispen er which attached to the 
monkey’s home cage during the testing session and was controlled by a computer.  
This pre-training (acclimation) task required the monkey to touch a single stimulus 
which appeared in a random location on the screen to receive the reward during each 
trial.  Rewards consisted of fruit flavored pellets.  Acclimation was continued until 
the monkey responded to 20 consecutive trials in one testing session.   
Animals that responded and reached criterion passed on to a simplified two-
choice conceptual set shifting task (CSST) to assess executive function and the ability 





time points throughout the study (Figure 2.1):  Baseline testing prior to the first 
injection of DSP4, 1 month after the high dose injection, after the second dose, and 
prior to necropsy.    The CSST task is divided intodiscrimination (OD) and reversal 
(RV) phases, monkeys responded by touching one of two objects presented on the 
screen: a green star or red star.  The location of both objects on the touchscreen varied 
with each trial and the maximum number of trials within a testing session was 60.  
During baseline OD, monkeys were trained to select the green star and the criterion 
for passing into the RV phase was 90% positive selections over 3 consecutive 
sessions.  Correct selection resulted in delivery of a fruit pellet.    After reaching 
criterion the animal switched to the RV phase and was rewarded for selecting the red 
triangle, the phase was continued until the individual reached a criterion of 90% 
positive selections over 3 consecutive days.  During each subsequent round of testing, 
beginning 30 days after injection of DSP4, the OD and RV stimuli were reversed 
(Table 2.2).  Total trials per session and errors were recorded during each round of 
testing. 
Table 2.2: Behavioral Testing Paradigm.  Alternating stimulus choice for each round of object 
discrimination (OD) and reversal (RV) testing. 
 
Round   Phase OD (S+) RV (S+) 
B Baseline Green Star Red Triangle 
1 DSP4; 40 mg/kg Red Triangle Green Star 
2 DSP4; 10 mg/kg Green Star Red Triangle 
3 DSP4; 10 mg/kg Red Triangle Green Star 
 
Statistics 
Data were analyzed by one-way ANOVA and directional contrasts were used 
to determine significant differences. The specific a priori hypotheses tested in this 





compared to age matched animals injected with vehicle (e.g. adult animals injected 
with DSP4 will have significantly depleted norepinephrine); (h2) aged animals 
injected with DSP4 will exhibit increased pathology compared to age-matched 
controls; (h3) aged animals would show significantly more pathology than adults.  
The number of planned comparisons for each dependent m asure was restricted (k−1) 
to test the three above hypotheses in order to minimize family wise type I error.  






DSP4 impairment of the catecholamine system  
Female adult and aged monkeys were treated with DSP4 3 times over 9 
months.   Levels of norepinephrine and dopamine were measured in locus coeruleus 
(Figure 2.2) along with cortical and subcortical regions (Figure 2.3, Figure 2.4) to 
assess alterations in tissue content in the treatment groups. In squirrel monkeys DSP4 
reduced norepinephrine in the locus coeruleus of adults (p=0.011).  Aged squirrel 
monkeys injected with DSP4 did not differ from aged controls (p=0.242).  Although 
there is a trend for age-related decline of norepinhrine, the decrease was not 
statistically significant (p=0.069, Figure 2.2A).  In rhesus monkeys, DSP4 depleted 
norepinephrine in the locus coeruleus of adults (p= 0.008).  Age alone did not reduce 
norepinephrine, adult and aged rhesus controls had similar levels of norepinephrine 
(p=0.373).   In aged rhesus DSP4 decreased norepinephr  (p=0.037) in the locus 





























































































































































































































































































































































































































































Mean norepinephrine values in cortical projection areas were slightly lower 
following DSP4 (Figure 2.3).  In adult squirrel monkeys (A) DSP4 reduced 
norepinephrine in the prefrontal cortex (p=0.041); whereas norepinephrine in rhesus 
monkey (B) temporal cortex was lower in aged controls c mpared to adults 
(p=0.046).  Mean norepinephrine content in remaining regions was not decreased 
when compared to controls in rhesus and squirrel monkeys (p > 0.10) following 
DSP4; with similar norepinephrine concentrations in remaining projection regions for 
adult and aged animals (p > 0.10).    
Subcortical projection (hippocampus) and non-projection (striatum) regions 
were evaluated for changes in norepinephrine content (Figure 2.4).  In the 
hippocampus variable results were noted across individuals; decreases were not 
detected in squirrel (A, p > 0.10) or rhesus females (B, p > 0.10) following DSP4 or 
with increased age.  In striatum, norepinephrine was elevated in adult squirrel 
monkeys after DSP4 (Figure 2.3A, p=0.010). No age-related alteration or change in 
aged animals following DSP4 (p > 0.10) or any rhesus monkey groups (p > 0.10) was 
detected. 
In squirrel monkeys DSP4 reduced mean dopamine in the striatum of adults 
(Table 2.3, p=0.02).  Remaining comparison between aged squirrel monkeys injected 
with DSP4 was not different nor was an age-related change detected in striatum (p > 
0.10).   Dopamine was not significantly altered in prefrontal cortex, hippocampus, or 
the locus coeruleus of squirrel monkeys (p > 0.10) and no group differences were 









































































Figure 2.3: Norepinephrine in cortical projection regions.Adult and aged squirrel 
monkeys (A) and rhesus monkeys (B) received 3 injections of DSP4 or vehicle (CON) over 
9 months.  Prefrontal cortex was most sensitive to DSP4 and an age-related decrease was 
detected in temporal cortex of rhesus monkeys.  Norepinephrine tissue content measured in 
brain punches collected after necropsy by ELISA and normalized to sample protein levels.  
DSP4 = 40 mg/kg, CON = saline vehicle, Bar graphs display Mean ± SEM.  * adult vs. 
aged control (p < 0.05), ** adult control vs. adult DSP4 (p<0.05), *** aged control vs. 



































































Figure 2.4: Norepinephrine in subcortical projection and non-projection region.Adult 
and aged squirrel monkeys (A) and rhesus monkeys (B) received 3 injections of DSP4 or 
vehicle over 9 months.  Variable response was detected in hippocampus of each species 
while an increase of norepinephrine was detected in the striatum of adult squirrel monkeys. 
Norepinephrine tissue content measured in brain punches collected after necropsy by 
ELISA and normalized to sample protein levels.  DSP4 = 40 mg/kg, CON = saline vehicle, 
Bar graphs display Mean ± SEM.  * adult vs. aged control (p < 0.05), ** adult control vs. 





   
Table 2.3: Dopamine in locus coeruleus, projection and non-projection regions.Adult 
and aged squirrel monkeys (A) and rhesus monkeys (B) received 3 injections of DSP4 or 
vehicle (CON) over 9 months.  Dopamine level was highest in striatum and a decrease was 
detected in adult squirrel monkeys after DSP4 injection.  Dopamine tissue content was 
measured in brain punches collected after necropsy by ELISA and normalized to sample 
protein levels. DSP4 = 40 mg/kg, CON = saline vehicl , * adult vs. aged control (p < 0.05), 
** adult control vs. adult DSP4 (p<0.05), *** aged control vs. aged DSP4 (p < 0.05)
Prefrontal Mean SEM % depletion Prefrontal Mean SEM % depletion
Adult Con 9.51 ± 4.38 Adult Con 23.12 ± 3.22
Adult DSP4 19.05 ± 13.01 -100.44 Adult DSP4 24.54 ± 5.87 -6.14
Aged Con 17.96 ± 2.43 -88.94 Aged Con 18.68 ± 6.10 19.20
Aged DSP4 12.44 ± 5.10 30.71 Aged DSP4 15.42 ± 2.88 17.45
Striatum Striatum
Adult Con 632.05 ± 134.94 Adult Con 780.94 ± 159.42
**Adult DSP4 31.85 ± 14.30 94.96 Adult DSP4 738.11 ± 148.59 5.48
Aged Con 413.01 ± 113.16 34.66 Aged Con 753.60 ± 162.82 3.50
Aged DSP4 447.38 ± 121.19 -8.32 Aged DSP4 741.00 ± 173.77 1.67
Hippocampus Hippocampus
Adult Con 13.03 ± 3.99 Adult Con 10.42 ± 4.22
Adult DSP4 5.71 ± 0.56 56.20 Adult DSP4 9.97 ± 2.68 4.32
Aged Con 5.49 ± 0.81 57.89 Aged Con 11.62 ± 3.28 -11.52
Aged DSP4 15.17 ± 9.21 -176.40 Aged DSP4 8.27 ± 4.25 28.83
Locus Coeruleus Locus Coeruleus
Adult Con 16.20 ± 8.96 Adult Con 21.06 ± 8.10
Adult DSP4 69.95 ± 54.19 -331.84 Adult DSP4 55.50 ± 28.22 -163.53
Aged Con 7.50 ± 2.40 53.67 Aged Con 15.88 ± 7.64 24.60
Aged DSP4 96.77 ± 90.87 -1189.69 Aged DSP4 61.76 ± 20.56 -288.9
(B) Rhesus Monkey
Dopamine (DA) pg/ ug protein
(A) Squirrel Monkey





Serial brain sections were collected and analyzed for opamine β-hydroxylase 
immunoreactive neurons (Figure 2.5) approximately midway along the rostro-caudal 
distance of the locus coeruleus where the cell density is high and significant cell loss 
has been documented in AD patients (Marien, Colpaert et al. 2004).  DSP4 reduced % 
area stained in aged rhesus monkeys (D, p=0.040); however there was no reduction 











































(C) Squirrel Monkey (D) Rhesus Monkey ***
Figure 2.5: Norepinephrine neurons in the locus coeruleus Photomicrograph through the locus 
coeruleus identifying dopamine β-hydroxylase neurons from the squirrel monkey (A) and rhesus 
monkey (B). Semi-quantitative determination of %area stained in serial sections through locus 
coeruleus of squirrel monkey (C,D). No difference in the squirrel monkey (C) and reduction in 
aged rhesus monkeys (D). DSP4 = 40 mg/kg, CON = saline vehicle, Bar graphs display Mean ±
SEM.  * adult vs. aged control (p < 0.05), ** adult control vs. adult DSP4 (p<0.05), *** aged 





DSP4 influence on Alzheimer’s-like pathology 
Serial brain sections were collected and analyzed for extracellular deposits of 
amyloid in frontal and temporal cortex along with hippocampus using 6E10 
immunostaining and congo red histological staining in adult and aged non-human 
primates.  An increase in % area stained for 6E10-immunostaining was detected due 
to aging in squirrel monkeys (Figure 2.6B, p=0.012); a trend for further increase due 
to DSP4 was noted however the effect was not statistically significant (p=0.059) for 
area stained.    Diffuse and compact morphology was observed in squirrel monkeys 
with pathology, with more pathology in deep layers of cortex and then extending into 
superficial layers in individuals with higher amounts of staining.  No pathology was 
observed in hippocampus or other subcortical regions.  
Amyloid staining identified by 6E10-IR was infrequent and isolated in rhesus 
monkeys; furthermore it was present only in the aged roups.  Total amyloid counts 
were significantly elevated with age (p=0.0001) andfollowing DSP4 (p=0.0001, 
Figure 2.7B).  Diffuse and compact staining was observed in neocortex and 
preferentially localized to deep layers in aged rhesus monkeys.  Subcortical areas 
were devoid of amyloid and all animals were congo red negative (Table 2.4) and 













Figure 2.7: Observed amyloid pathology in rhesus monkeys.  Photomicrographs 
of 6E10-IR in representative areas of frontal cortex of the rhesus monkey (A), 
observed amyloid morphology (B) and % area stained for each treatment group (C). 
DSP4 = 40 mg/kg, CON = saline vehicle, Bar graphs display Mean ± SEM.  * adult 
vs. aged control (p < 0.05), ** adult control vs. adult DSP4 (p<0.05), *** aged 



















































































































































































































































































































































































































































































































Tissue punches from prefrontal and temporal cortex w re prepared for soluble 
amyloid-β40 and amyloid-β42 ELISAs to determine the ratio of isoforms in each 
cortical region. The ratio of soluble Aβ42:Aβ40 increased in aged squirrel and rhesus 
monkeys after DSP4 animals (Figure 9).  The response was highly variable in PF-C 
(p > 0.10) and significantly elevated in TEM-C (p = 0.003) from squirrel monkeys 
(Figure 9A).  In aged rhesus monkeys, the ratio was significantly elevated in both 
prefrontal (p = 0.025) and temporal cortex (p = 0.028).  In adult squirrel and rhesus 
monkeys the ratio was not elevated after DSP4 (p > 0.10).  A trend for an age-related 
increase was noted in squirrel monkeys (p = 0.054), however no difference between 




























































































































































































































































































































Conceptual Set Shift Testing 
Analysis of behavioral testing data using repeated m asures revealed no 
significant interaction between testing round and group for OD-errors (p > 0.10) and 
RV-errors (p > 0.10); although a significant effect of ime for OD-errors (p=0.003) 























































































































































































































































In the current study, increased age and long-term norepinephrine depletion in 
the locus coeruleus with DSP4 increased amyloid-β pathology in cortical regions of 
non-human primates. Nearly twice as much amyloid was observed in depleted aged 
animals of both species.  While previous studies with transgenic AD-animals and 
post-mortem examination of AD-human brains show significant loss of 
norepinephrine neurons in the locus coeruleus (Zarow, Lyness et al. 2003; O'Neil, 
Mouton et al. 2007) a reduction with age was not observed in either non-human 
primate species examined in this study.   
Conflicting reports on the degree and duration of norepinephrine depletion 
due to DSP4 are interwoven with dosing paradigm.  Differences between studies 
include the amount injected, number of injections provided and timeframe.   Early 
experiments also demonstrated that sensitivity often differed with strain and species 
(Jaim-Etcheverry and Zieher 1980; Jonsson, Hallman et al. 1981; Grzanna, Berger et 
al. 1989; Fornai, Bassi et al. 1996).  In contrast to previous experiments with DSP4 in 
AD transgenic mice which most often utilized multiple high dose injections; the 
paradigm used in the current study did not produce a p rmanent or long-lasting lesion 
in adult monkeys although the long-term reduction of orepinephrine suggests that 
locus coeruleus function was impaired by DSP4.  These r sults also support the 
primary action of DSP4 was not restricted to locus oeruleus terminals and that direct 
influence of DSP4 also occurred at locus coeruleus c ll bodies through action at 
norepinephrine transporters (Ordway, Stockmeier et al. 1997; Sanders, Happe et al. 





with reduced norepinephrine content in the locus coeruleus support the notion that 
increased activity could compensate for a subset of impaired neurons (Szot, White et 
al. 2006); although locus coeruleus dysfunction still permits increased amyloid 
deposition.  A novel finding in this study, specifi to the adult squirrel monkeys, was 
elevated norepinephrine and decreased DA in striatum following DSP4.  This result 
was indicative of further adaptive changes within te monoaminergic system; 
however the mechanism or benefit remains unclear.  Non-coeruleun noradrenergic 
projections may contribute to the increase, althoug the corresponding decrease of 
DA within the local environment suggests a role for increased dopamine β-
hydroxylase activity.       
Species comparison of dopamine β-hydroxylase immunoreactivity indicated 
that the rhesus monkey locus coeruleus was approximately twice the size of the 
squirrel monkey locus coeruleus.  This was not surprising given the difference in 
brain size and trends noted in other primate species regarding neuronal number in the 
locus coeruleus (Sharma, Xu et al. 2010).  Interpretation of squirrel monkey 
dopamine β-hydroxylase immunoreactivity was hampered by low sample size and for 
this endpoint only 1 aged control was measured due to improper hemi-section during 
tissue processing.  However, the individual measured had lower localization of 
dopamine β-hydroxylase when compared to the adult group and co sidering the age-
related loss of norepinephrine in aged squirrel monkeys it appeared feasible that 
neuronal loss might contribute to the reduction.  I the rhesus monkey, slight 
reduction of dopamine β-hydroxylase detected at necropsy in adults following DSP4 





moderate recovery within weeks to months following single injections of DSP4 has 
been reported in young rodents (Jonsson, Hallman et l. 1981; Fornai, Bassi et al. 
1996); Szot et al. (2010) report restored norepinephrine tissue content in locus 
coeruleus and projection regions 3 months following a single injection of DSP4 in 
Spraque-Dawley rats.  The long-term reduction of dopamine β-hydroxylase 
immunoreactivity and decreased norepinephrine afterDSP4 in aged rhesus monkeys 
demonstrated that they may be more sensitive to long-term effects of DSP4 and thus 
less able to recover after exposure.  In that regard the results discussed here are 
striking, considering the parameters of DSP4 dosing and 3 month period between 
injections.  The long term decrease of norepinephrine in the locus coeruleus after 
DSP4 in both adult and aged groups contributed to increased amyloid in adult and 
aged squirrel monkeys along with aged rhesus monkeys.  
Similar to humans, an age-related increase of amyloid occurred in both 
squirrel and rhesus monkey brain.   Consistent withother reports of cerebral amyloid 
in non-human primates, diffuse and compact extracellular amyloid pathology in 
squirrel monkeys was observed in frontal and temporal cortex; rhesus monkey 
pathology was infrequent and isolated in cortex.  In both species more amyloid was 
measured following DSP4 injection (Figure 2.6 and Figure 2.7) and these results 
demonstrated that norepinephrine depletion contributed to the deposition and 
accumulation of amyloid in the neocortex of aged rhesus monkeys.  The earlier onset 
of pathology in adult squirrel monkeys suggests locus oeruleus impairment may also 
accelerate pathology.  Locus coeruleus degeneration has been reported in cases of 





AD (Grudzien, Shaw et al. 2007).  A more pronounced effect of DSP4 on amyloid 
occurred in squirrel monkeys due to dense reciprocal fiber connections between the 
FC and locus coeruleus; compared to other regions the transient loss of 
norepinephrine exacerbated FC more extensively and squirrel monkeys were more 
sensitive due to their relatively older age compared to rhesus monkeys.  Loss of 
norepinephrine also altered the ratio of soluble amyloid in cortical regions from aged 
animals, soluble monomers represent an earlier stage of pathology and results suggest 
DSP4 also influences the generation and aggregation of amyloid isoforms.   
Importantly, elevated levels of these monomers and oligomers correlate better to 
impaired cognition in AD patients and in animal models soluble oligomers impair 
synaptic function. 
Executive functions decline in AD and the locus coeruleus regulates attention 
and decision making processes involved in executive function tasks mediated by 
prefrontal cortex (Chang, Jacobson et al. 2009).  Studies with non-human primates 
have illustrated activation locus coeruleus neurons during behavioral tasks which 
require a change in attention or an alteration in the reinforcement paradigm during a 
testing session (Rajkowski, Majczynski et al. 2004).  Analysis of behavioral data did 
not reveal significant differences in object discrimination or reversal endpoints.  
While animals improved over time, total number of trials and errors for each testing 
phase were not different between treatment groups.  Taking into account depletion 
data from the pilot study where levels of norepinephrine were affected to a greater 
degree at 30 days suggested increased activity in the locus coeruleus could be 





adequately.  Over the long term the DSP4 injection schedule may have been 
insufficient to cause long lasting cortical differenc s in norepinephrine, equivalent 
performance on this behavioral task is less surprising during round 2 and 3 given the 
lower dose of DSP4 used in the study and lack of permanent lesion.  Additional 
factors such as anxiety and motivation also contribu e to individual performance.   
 The goal of this study was to determine if DSP4 could induce and increase 
cerebral amyloid pathology in two species of non-human primates which develop 
amyloid deposits naturally.  The results from both squirrel and rhesus monkeys 
support the experiments suggesting that locus coeruleus impairment plays a role in 
the development of AD.    The data discussed here highlight the importance for 
considering dosing paradigm used to induce degeneration, in future studies it would 
be beneficial to use low dose chronic infusions of DSP4 to better mimic a gradual 
decline similar to what was done in Kalinin, Gavrilyuk et al. (2007) study with a 
transgenic mouse model or consider monthly injections t  ensure a long-lasting 
lesion.  Compensatory actions and recovery mechanisms are interesting mediators to 
overall dysfunction but require further experiments to elucidate their contribution in 





Chapter 3: Altered amyloid precursor protein processing in non-
human primates with impaired locus coeruleus functio  
Introduction  
Degeneration in the locus coeruleus is a major pathological feature of 
Alzheimer’s disease (AD); studies have demonstrated neuronal loss and dysfunction 
occur early in progression of pathogenesis (Mann, Li coln et al. 1980; Bondareff, 
Mountjoy et al. 1982; Grudzien, Shaw et al. 2007).  In efforts to explain the cognitive 
decline and pathological changes occurring with AD,the cholinergic system received 
much consideration with observations of neurochemical deficits in choline 
acetyltransferase and neuronal loss in basal forebrain resulting in presynaptic decline 
in acetylcholine contributing to memory problems (Bartus, Dean et al. 1982; 
Whitehouse, Price et al. 1982).  The cholinergic hypothesis gained traction within the 
AD field, while concurrent observations regarding the locus coeruleus were generally 
overlooked.    Interest in the locus coeruleus and the contribution of locus coeruleus 
projections to AD gained attention when Zarow and colleagues (2003) reported more 
cell loss in the locus coeruleus compared to basal forebrain of AD patients.  
Subsequent studies utilizing animal models provided further evidence for interactions 
between amyloid pathology and locus coeruleus impairment (Heneka, Ramanathan et 
al. 2006; Jardanhazi-Kurutz, Kummer et al. 2010; Lockr w, Boger et al. 2011). 
 Distribution of norepinephrine is regulated by thelocus coeruleus, which is 
the main site of central nervous system synthesis.  Cortical and subcortical regions 
receive noradrenergic input and utilize norepinephrine in a variety of receptor-





attentional behavior and extrasynaptic mediation of i flammatory responses from 
neurons and neuroglia (Feinstein, Heneka et al. 2002; Marien, Colpaert et al. 2004; 
Sara 2009).  In the central nervous system, norepinephrine suppresses inflammatory 
gene expression and reduces inflammatory responses by suppression of cytokine 
production (Galea, Heneka et al. 2003; Madrigal, Feinst in et al. 2005; Heneka, 
Nadrigny et al. 2010) thus acting in a neuroprotectiv  capacity.  In addition to 
deposition of amyloid, AD transgenic mouse models with experimentally depleted 
norepinephrine exhibited increased neuroinflammatory markers including sustained 
microglia and astrocyte activation along with elevat d pro-inflammatory cytokine 
release (Heneka, Ramanathan et al. 2006; Pugh, Vidgeon-Hart et al. 2007; 
Jardanhazi-Kurutz, Kummer et al. 2010). 
 The mechanisms responsible for increased AD pathology due to locus 
coeruleus degeneration are not clearly understood or established.  Generation of 
amyloid-β occurs through processing of amyloid precursor protein and sequential 
cleavage by β- and γ- secretase (Hardy and Selkoe 2002).   Levels of amyloid-β are 
regulated by differential activity in production, clearance and degradation pathways 
(Wang, Wang et al. 2010).  Post-processing clearance of amyloid isoforms occurs 
through blood-brain barrier dynamics and multiple degradation mechanisms, 
including the protease neprilysin and microglial phagocytosis.   Thus, an imbalance 
due to increased amyloid-β synthesis along with decreased clearance contributes to 
aggregation of amyloid and the pathological progression of AD (Miners, Baig et al. 
2008).  In AD transgenic mice, reduced neprilysin and elevated amyloid deposition 





Gavrilyuk et al. 2007).  Further, addition of norepinephrine in microglia culture 
effectively enhanced uptake and degradation of Aβ mediated through adrenergic 
receptor signaling (Kong, Ruan et al. ; Heneka, Nadrigny et al. 2010).     
 Locus coeruleus impairment and norepinephrine depletion could contribute to 
amyloid pathology from uncontrolled inflammation due to reduced anti-inflammatory 
regulation or directly alter amyloid precursor protein processing.  Furthermore, 
because neuroglia far outnumber neurons in the central nervous system, resulting 
dysfunction in astrocytes and microglia could contribute significantly to development 
of pathology.   The aim of the current study was to examine the role of 
norepinephrine depletion on elevated amyloid deposition n non-human primates.  
Non-human primates develop amyloid pathology naturally which was exacerbated by 
reduced norepinephrine in the locus coeruleus due to systemic injection of DSP4 
(Chapter 2).   Therefore this model provides the opportunity to examine pathways 
responsible for the elevation of pathology using non-transgenic animals, specifically 
the contribution of neuroinflammation and pathogenic changes in APP processing in 






Materials and Methods 
Subjects 
Pilot study: 3 female adult common squirrel monkeys (Saimiri sciureus, aged 
15 years) and 3 female adult rhesus monkeys (Macacca mulatta, aged 15-16 yrs) 
were studied in an initial short-term study (Table 1).  Long term study: 8 adult (11 
years old) and 5 aged (19-20 years old) squirrel monkeys were studied.    
Additionally, 14 adult (14-17 years old) and 7 aged (19-25 years old) rhesus monkeys 
were studied (Table 1).  All monkeys were female. 
Animals were obtained from approved sources and maintained at the National 
Institute on Aging/NIH primate facility prior to the study.  Animals were housed in 
standard non-human primate caging  and kept on 12:12hr light cycle, had ad libitum 
access to water and were fed standard NIH diet twice daily approximating ad libitum 
levels.  Animals were observed daily by trained observers, including checks on food 
consumption and well-being.  Routine health monitoring, TB tests and blood 
collections were done quarterly.   
Animal husbandry and all experimental procedures in the study complied with 
the National Institutes of Health Guide for the Care nd Use of Laboratory Animals 
and were conducted under an approved protocol by the NIA Institutional Animal Care 
and Use Committee (IACUC).  In addition, an IACUC protocol was also approved at 
the University of Maryland for all experiments utilizing non-human primate tissue 







Table 3.1: Animal Distribution and Treatment Groups.  All animals were housed at the National 
Institute on Aging (NIA) primate facility.  
 
*One adult squirrel and one aged rhesus animal died before the end of study 
 
Experimental Design 
Previous work with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) 
in several other species consistently reported norepinephrine depletion with a dose of 
50 mg/kg (Heneka, Ramanathan et al. 2006; Waterman and Harding 2008).   A short-
term pilot experiment was conducted to confirm the utility and dosage of the 
neurotoxin in non-human primates.  Two adults served as controls and  received an 
injection of saline vehicle; while 4 adults received an injection of N-(2-chloroethyl)-
N-ethyl-2-bromobenzylamine (DSP-4; 50 mg/kg). All animals were necropsied 30 
days post injection (Table 3.1).   
In the long-term study (Figure 3.1), 10 adult and 7 aged animals received 3 
injections DSP-4 spaced 3 months apart (n=17);  controls received th saline vehicle 
(n=14; Table 3.1).  To minimize transient peripheral side effects the dose used in the 
long term study was lowered to 40 mg/kg for the initial dose and 10 mg/kg for 
Species Age Group Study Treatment n 








20 Aged Con 2 
11 Adult DSP-4 4* 










19-25 Aged Con 3 
14-17 Adult DSP-4 6 





subsequent dosing. To prevent incidental serotonergic depletion each animal first 
received an intraperitoneal (i.p.) injection of Zimelidine (Sigma: 10 mg/kg).  The 
initial DSP-4 dose (Sigma: 40 mg/kg, i.p.) was administered 45 minutes later.  
Subsequent injections of Zimelidine followed by DSP-4 (10 mg/kg, i.p.) or vehicle 
were administered at the 3 and 6 month time points.  Blood was collected prior to 
each injection series.  Three months after the final injections animals were necropsied  
   
 
Figure 3.1: Long Term Study Design. Squirrel and Rhesus monkeys were injected 3 times with 
indicated dose of DSP4 over 9 months. 
 
Tissue Collection 
Animals were restrained with ketamine and both blood and cerebrospinal fluid 
were collected.  Animals were deeply anesthetized using B-euthanasia-D (80 mg/kg, 
IV) and then perfused transcardially with cold 0.9% saline.  Brain tissue was prepared 
for biochemical and immunohistochemical assays.  Each brain was divided along the 
medial longitudinal fissure and blocked in 1 cm increments using an adult monkey 
coronal brain matrix with 2mm slots.  The right half was immediately frozen in 












was immersion-fixed in 4% paraformaldehyde for 48 hrs, placed through a series of 
graded sucrose solutions until blocks sank in 30% sucrose and then frozen at -80°C.     
 
Immunohistochemistry (IHC) 
Fixed blocks were sectioned (50µm) on a freezing sta e sliding microtome 
and placed into cryopreservation buffer for storage t -20°C until immuno-histo-
chemical (IHC) staining.  Serial sections were collected from blocks throughout the 
brain to examine frontal cortex, hippocampus, pariet l, ntorhinal and temporal 
cortex.  Regions of interest were delineated based on landmarks from a rhesus 
monkey stereotaxic atlas (Paxinos and Watson, 2009).  Subsets were stained with the 
following antibodies: Anti-GFAP Ab-4 (1:500, Thermo Scientific, Freemont CA), 
Anti-IBA1 (1:3000, Wako Chemicals, Richmond VA), Anti-MHCII HLA-DR Clone 
LN-3 (1:1000, Pierce, Rockford IL), Anti-CD10 (1:100 , Acris, San Diego CA) 
Stained sections were mounted onto PLUS slides and allowed to air dry for 3 
days. Slides were counter stained with 2% cresyl violet and/or 5% congo red 
solutions, dehydrated, and then cover-slipped using permanent mounting medium. 
Slides dried for 1 week to assess microglia and astrocyte morphology along with 
neprilysin distribution.  Images were analyzed using ImageJ (NIH) to analyze specific 
staining patterns for each antibody.  Thresholding was adjusted to isolate positively 
stained regions from background to determine % area stained.  In cresyl violet co-
stained tissue size criteria were added to exclude cresyl violet stained nuclei and to 
ensure % area reflected only staining for each primary antibody.   Three non-





serial sections spaced 500µm apart from each animal and averaged to obtain a semi-
quantitative measure of % area stained. 
Enzyme Linked Immuno Sorbet Assays (ELISAs) 
Serum, cerebrospinal fluid and cerebral cortex brain homogenate samples 
were prepared and analyzed for inflammatory markers analysis. Brain punches were 
collected from fresh-frozen tissue blocks and homogenized (Fisher Scientific 
PowerGen125) in 0.1N HCL, centrifuged (15k G) for 15 minutes at 4°C, and the 
supernatant was collected for subsequent ELISA procedures.  Monkey interleukin -6, 
rhesus monkey tumor necrosis factor-α, and human interleukin-1β (Invitrogen, 
Camarillo, CA) were assayed according to the manufact rer’s instructions.  All 
samples were run in duplicate. Absorbance values were m asured by microplate 
reader (BioRad 480) with a 450nm filter.  The averag  optical density values for each 
region were interpolated on 4-PL standard curves to de ermine levels of pro-
inflammatory cytokines. Levels in brain homogenate were standardized by sample 
protein levels measured using the BCA method (Pierce-Thermo Scientific, Rockford 
IL). 
Luminescence Assays 
Baseline, 3 month, and end of study serum samples were analyzed for Caspase 
3/7 and Caspase 9 activity according to the manufact rer’s standard protocol 
(Promega, Madison, WI).  Briefly, a 25 ul sample was mixed gently for 30s with 25 
ul Caspase-Glo 3/7 reagent in white-walled 96-well plates and incubated for 2h at 





and stripped serum served as a negative control.  All samples were run in duplicate.  
Luminescence was measured using a Biotek Synergy HT plate reader and values were 
expressed as relative intensity units (RIU).  Relative intensity values were normalized 
to individual baseline values and then examined for gr up differences.    
Western Blot Analyses 
Sample lysates from prefrontal and temporal cortex w re prepared using M-
PER (Pierce, Rockford IL) to analyze levels of amyloid precursor protein (APP) and 
β-site APP cleaving enzyme-1.  An equal amount of lysate protein was loaded onto 
10% polyacrylamide gels containing SDS.  SDS-PAGE was run and transferred to 
PVDF membranes. The membranes blocked for 1 h in nonfat milk; then incubated 
overnight with primary antibodies against APP-CT (Calbiochem, Billerica MA), 
BACE-1 (3D5) and β-actin (Sigma, St Louis MO). Membranes were then incubated 
with secondary antibody for 1 h.   Bands were visual zed and normalized to β-actin. 
Statistics 
Data were analyzed by one-way ANOVA and directional contrasts were used 
to determine significant group differences. The specific a priori comparisons used 
were (1) adult animals injected with DSP4 vs. adult CON (2) aged animals injected 
with DSP4 vs aged CON and (3) aged animals vs. adults to test whether development 
of amyloid pathology in animals with impaired LC function occurs due to increased 
neuroinflammation, apoptosis, and altered APP processing.  The number of planned 
comparisons for each dependent measure was restrictd (k−1) to test the above 






Evaluation of Neuroinflammation 
Markers of inflammation were examined in serum, cerebrospinal fluid, and 
brain homogenate. Level of interleukin-6 was elevatd in aged squirrel monkeys after 
DSP4 (p=0.0484), however remaining comparisons were not increased in either 
species (p > 0.10).  Tumor necrosis factor-α level in adult compared to aged squirrel 
monkeys was increased (p=0.0015); while remaining comparisons were not elevated 
(p > 0.10) at the 9-month time point in brain homogenate; serum collected at 
necropsy and cerebrospinal fluid were below assay detection.  In all samples, results 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Microglia were assessed using IBA1-IR and identification of cell hypertrophy 
to distinguish resting and activated microglia (Streit, 2009).  Microglia cells were 
widely distributed throughout the brain (Figure 3.2A) and an activated morphology 
was rarely observed (Figure 3.2B).  The % area stained was determined for each 













Astrocyte distribution and morphology were examined using GFAP-IR in 
grey matter and white matter regions (Figure 3.3).  GFAP-IR in grey matter was very 
low and when present was associated with vasculature, GFAP was constitutively 
expressed in white matter and cell body morphology showed no sign of hypertrophy.  













Analysis of cell-death related pathways 
In order to examine intrinsic and extrinsic apoptosis pathways as potential 
biomarkers, caspase 3/7 and caspase 9 were measured in serum collected at baseline, 
3-month, and necropsy.  3-month and necropsy measurments were normalized to 
baseline and analysis revealed an increase of caspase 9 in adult rhesus monkeys 
following DSP4 (p = 0.015, Figure 3.4B).  Remaining comparisons of caspase 3/7 










































































































































































































































































































































































































































































































































































Examination of APP processing 
In order to assess production and cleavage of amyloid precursor protein (APP) 
after DSP4, levels of intracellular APP and β-site APP cleaving enzyme-1 were 
determined in frontal and temporal cortex. In squirrel monkeys APP increased in 
frontal cortex (p = 0.032) with aging; β-site APP cleaving enzyme-1 also increased 
with age in frontal (p = 0.038) and temporal cortex (p = 0.016).  However, DSP4 did 
not further exacerbate these age-related changes.  In rhesus monkeys there was an 
age-related increase of APP in temporal cortex (p = 0.0004) and DSP4 treatment 
increased APP in adults (p = 0.00006).  Additional i creases of β-site APP cleaving 
enzyme-1 following DSP4 were detected in frontal cortex of aged rhesus monkeys (p 






















































































































































































































































































































































































































To examine amyloid precursor protein degradation, the protease neprilysin 
(CD10) was examined in non-human primate frontal cortex, striatum, hippocampus 
and temporal cortex.  Neprilysin immunoreactivity was observed and widely 
distributed in the rhesus monkey striatum (Figure 6A), but was not present in other 
brain regions.   Analysis of % area stained showed equivalent staining in all groups 














These experiments were focused on revealing potential mechanisms and 
pathways impacted by DSP4 treatment in adult and age  female non-human primates, 
contributing to the elevation of amyloid pathology in non-human primates reported 
previously (Chapter 2).  We chose markers for serum and cerebrospinal fluid for 
neuroinflammation, apoptosis and amyloid precursor pr tein processing in AD 
relevant brain regions to elucidate the mechanisms nfluencing amyloid accumulation 
in animals with impaired locus coeruleus function and significant long term reduction 
of norepinephrine.   Here we demonstrated that norepinephrine depletion increased 
levels of β-site APP cleaving enzyme-1, the secretase enzyme responsible for 
pathogenic formation of amyloid-β, and also influenced amyloid precursor protein in 
the absence of chronic neuroinflammation.   
Microglia cells are located throughout the central nervous system and are 
critical transducers of neuroimmune responses to inflammation.  Activated microglia 
are essential for phagocytosis of damaged cells and debris.  Microglia respond 
quickly to central nervous system injury and are important for clearance of amyloid 
with chronic activation occurring during disease (Streit, Mrak et al. 2004).   After 
injury microglia increase in cell number, change morph logical appearance, and 
migrate to site of trauma during activation.  These microglia regain their resting state 
morphology after the return of homeostasis while sustained microglial activation 
results in increased and aberrant production of pro-inflammatory cytokines which 
contribute to further damage to surrounding tissue.  Numerous AD-transgenic mouse 





increased secretion of proinflammatory cytokines from microglia (Heneka, 
Ramanathan et al. 2006; Heneka, Nadrigny et al. 2010).  In our study the morphology 
of Ibal1 immunoreactive stained microglia across age nd treatment showed no 
evidence for activation necessary for release of pr-inflammatory cytokines and the 
widely distributed uniform appearance of Iba1 positive microglia was typical of a 
resting phenotype without proliferation.  These results indicated that chronic 
neuroinflammation did not occur with our DSP4 dosing paradigm in non-human 
primates.  Further our experimental design allowed for sufficient time between 
injections to restore a resting state within the microglia population.   
Astrocytes make extensive contacts with blood vessels and play a 
neurosupportive role in conjunction with the Blood-Brain-Barrier; aiding homeostasis 
through interactions with neurons. The GFAP protein was isolated from a 
pathological disease state and is consequently very sensitive to detection of reactive 
astrogliosis but does not label all non-reactive astrocytes (Sofroniew and Vinters 
2010).  In white matter GFAP can also be used as a general indicator for blood-brain 
barrier integrity (Liedtke, Edelmann et al. 1996).  Similar staining across groups 
demonstrated normal blood-brain barrier morphology and provided evidence for 
proper myelination of axons, which are densely populated within white matter brain 
regions.  The lack of proliferation or increase in cell hypertrophy in grey matter 
regions supported the conclusion that the dosing paradigm did not induce chronic 
neuroinflammation and astrocyte function was maintained at the conclusion of this 
study.  Further, the presence of increased amyloid (Chapter 2) without coexisting 





alone were not sufficient to cause a sustained inflammatory response. Relatively low 
levels of oligomeric and fibrillar species of amyloid-β compared to higher levels of 
diffuse amyloid-β deposition might contribute to the lack of activaton due to amyloid 
alone (Stalder, Phinney et al. 1999; White, Manelli et al. 2005; Sondag, Dhawan et al. 
2009).  
Cytokines are central to both pro and anti-inflammatory pathways in the brain 
and are a key regulator of neuro-immune responses icluding modulation of 
inflammation.  After insult to the central nervous system and during subsequent 
inflammatory response, microglia and astrocytes release cytokines into the local 
environment. Acute release of inflammatory cytokines is essential for stimulating 
appropriate reparative processes and acts in a generally beneficial manner; however 
under pathological conditions damage increases and persistent activation is 
considered an important component of neurological diseases including AD (Dello 
Russo, Boullerne et al. 2004).  Levels of pro-inflammatory cytokines are generally 
very low or even undetectable in normal brain, however they become rapidly induced 
following injury or sustained release during disease (Allan, Tyrrell et al. 2005).  
Notably interleukin-1β, tumor necrosis factor-α and interleukin-6 are localized close 
in close proximity to amyloid plaques in AD (Cacquevel, Lebeurrier et al. 2004); and 
amyloid deposits perpetuate the release of more interleukin-1β, driving the cycle of 
aberrant cytokine expression (Forloni, Demicheli et al. 1992).  Inflammatory 
cytokines measured in this study were below detection in cerebrospinal fluid and sera 
from both species; low levels and small increases of interleukin-6 were detectable in 





postulated as potential biomarkers for AD; however, conflicting results from clinical 
studies examining serum and cerebrospinal fluid bring their utility as biomarkers into 
question (Mrak and Griffin 2005; Schuitemaker, Dik et al. 2009).   These data, along 
with IBA1 and GFAP immunoreactivity, supported the conclusion that 
neuroinflammation was not persistent or heightened by the end of the long term 
study.   Transient increases of neuroinflammation ca not be ruled out and based on 
the literature likely do contribute to the longterm effects on amyloid deposition in a 
short or intermediate manner not picked up in this study.  Data from our short term 
pilot study (appendix) demonstrated more depletion c mpared to the longterm study 
and the elevated inflammatory measures in brain homogenate provided some initial 
evidence to support this conclusion.  
Extrinsic signals, such as binding at the TNFα receptor, and intrinsic 
mitochondrial pathways contribute to neuronal cell d ath via caspase-3 (Cas3) 
activation.  Cas3 is a key enzyme in apoptosis cell-signaling cascades and also acts on 
a caspase cleavage site on the cytoplasmic domain of myloid precursor protein to 
form the C31 fragment.  This fragment further contributes to apoptosis in AD by 
complexing with amyloid precursor protein to enhance signals related to 
neurotoxicity (Bertrand, Brouillet et al. 2001; Park, Shaked et al. 2009).   Intrinsic 
activation may alter mitochondrial membrane permeability, thereby releasing 
cytochrome c, which then interacts with caspase-9 upstream of cas3.   Observations 
of cas3/7 and cas9 activities from both species showed trends for increased activity in 
rhesus monkeys at the 3-month and necropsy time points following injection with 





serum from adult rhesus monkeys 3 months after the high dose of DSP4, indicating 
transient increase of mitochondrial membrane permeability or possible activation by 
C31 (Lu, Soriano et al. 2003); however, a change in the periphery might also 
contribute to an elevation of caspase 9 in serum and further investigation would be 
required to determine brain specific effects.  Given the lack of cytokine activation and 
probable recovery between injection time points, the rhesus monkeys may be more 
sensitive to long term changes in caspase activity.  The transient nature of the effects 
after the DSP4 treatment paradigm implies a more continuous exposure or repeated 
high doses through the experiment may have been more effective in sustained 
elevations of these biomarkers and more effective in chronic elevations reported in 
AD.   
 The accumulation of various amyloid isoforms and plaque formation occurs 
through an imbalance between amyloid-β production and clearance. Pro-
inflammatory cytokines have been shown to modulate p hogenic amyloid precursor 
protein processing, increasing generation of amyloid precursor protein itself and 
elevated β-secretase cleavage (Moore and O'Banion 2002; Bourne, Ferrari et al. 2007; 
Carrero, Gonzalo et al. 2012); while neuroglia and proteases actively degrade 
amyloid (Hersh and Rodgers 2008; Lee and Landreth 2010; Pihlaja, Koistinaho et al. 
2011).  Age related changes in amyloid precursor prtein and β-site APP cleaving 
enzyme-1 were detected in the squirrel monkey; however DSP4 did not increase 
either endpoint in frontal or temporal cortex.   Elevated amyloid deposition was 
reported in these animals (Chapter 2) and the age-related increase can be partially 





amyloid deposition after DSP4 in squirrel monkeys cannot be explained by long-term 
changes in amyloid precursor protein processing. However, transient increases in 
inflammation or reduced degradation would explain the increase.  DSP4 also 
increased amyloid deposition in neocortex of rhesus monkeys and the sustained 
elevations in APP and β-site APP cleaving enzyme-1 detected following injection 
with DSP4 suggest altered amyloid precursor protein processing contributed to 
increased deposition.  The Aβ degrading enzyme neprilysin was detected in the 
striatum of rhesus monkeys; however IR was not significa tly decreased after DSP4.  
Thus the elevation in APP and increased pathogenic cleavage by β-site APP cleaving 
enzyme-1 both contribute to the elevation of amyloid deposition in rhesus monkeys, 
rather than a decreased degradation of amyloid-β by neprilysin.   
 In summary, DSP4 treatment effectively accelerated th  onset and incidence 
of AD-like pathology in non-human primates due to altered APP processing.  This 
provides support for the contribution of impaired noradrenergic systems in 
progression of AD pathology and elucidated some of the pathways involved in 
amyloid accumulation following long term depletion f norepinephrine in the locus 
coeruleus.  Specifically, our findings reveal that the long term reduction of 
norepinephrine contributed to increased amyloid pathology due to altered APP 
processing and not degradation via neprilysin. Furthermore, these long lasting 






Chapter 4:  Concluding Remarks 
Overall Discussion 
Understanding the neurobiological basis for the accumulation of pathology in 
AD remains elusive.  Studies focused on charactering the neuropathology in 
transgenic AD-mouse models but often focused on degen ration in basal forebrain, 
hippocampus, and temporal cortex.  Despite the challenges of small sample sizes, 
heterogeneous sample populations and individual variation our findings provide 
valuable insights into the role of the noradrenergic system as a key component in AD 
associated neurodegenerative processes.  Moreover, the data presented in Chapters 2 
and 3 builds the groundwork to demonstrate an influe ce of locus coeruleus-
norepinephrine changes in non-human primates that develop amyloid pathology in an 
idiopathic manner. 
It is remarkable to observe significant long-term changes in AD pathology 
based on impairment of a single small population of eurons.  The observation of a 
significant change from permuting one neurotransmitter system is significant because 
it illustrates the importance of the norepinephrine system in the upregulation and 
accumulation of amyloid pathology.  At the same time, our experiments also 
demonstrated resilience in norepinephrine and associated other neural systems in 
regard to mediating a neurotoxic insult and minimizng chronic neuroinflammation.  
The potential for recovery of norepinephrine contaiing neurons projecting to AD 
sensitive regions is further evidence for a capacity for compensation by multiple brain 
systems.  This capacity also highlights the importance of redundancy in neural 





types of mechanisms allow organisms to potentially cope with loss of neurons and 
resulting dysfunction up to a point, until multiple n tworks fail resulting in significant 
disease progression.   
The brain uses a series of checks and balances.  Within this complex tapestry, 
norepinephrine provides wide-ranging modulation throughout the cortex.  Based on 
our data, the loss of norepinephrine neural systems in key areas of the brain appears 
to be permissive for the accumulation of amyloid pathology, thereby contributing to 
the development of AD.  In the short-term experiment, widespread norepinephrine 
depletion in the locus coeruleus, cortical and subcortical regions resulted in evidence 
of inflammatory responses at 30 days following a single injection of DSP4.  
Conversely, the treatments and measurements taken 3 months after the final dosing in 
the long-term study provides evidence to support the restoration of norepinephrine in 
cortical regions may occur at the expense of developing AD pathology.   Considering 
the long-term reduction of norepinephrine in the locus coeruleus, the brain may 
compensate for loss of norepinephrine in the case of limited physiological functions.   
However, the norepinephrine compensation did not appe r to be adequate to modulate 
processes that contribute more directly to increased Aβ production or decreased 
clearance.   
Contributions from biology-related fields and medicine have dramatically 
enhanced our understanding of the brain and central ne vous system.   Neuroscience 
and molecular biology techniques are ever evolving a d have made incredible 
technological advances in the last few decades helping scientists to further their study 





likely caused by a complex interaction of environmetal and genetic factions leading 
to eventual dysfunction.  There is no single risk factor or cerebral alteration that 
guarantees a shift to an Alzheimer’s phenotype of pr gressive and severe cognitive 
decline.   
So why are humans so susceptible to Alzheimer’s disease?  One answer is that 
we live too long; specifically we outlive our reproductive lifespan.  This may also be 
a contributing factor for higher incidence of AD in women than men; perhaps due in 
part of the menopausal related loss of gonadal steroids.  Genetic lineages for human 
and ape separated about 7 million years ago with significant differences in maximum 
lifespan between the species; maximum lifespan for the rhesus monkey is 40, while 
the oldest living female human died at the age of 122.  AD pathology occurs late in 
life, well beyond reproductive senescence but at least a decade before the average 
mortality in the United States.  In contrast, the majority of non-human primates do not 
survive long after reproduction stops and the prevalence of Alzheimer’s-like 
pathology is lower compared to humans.  Perhaps the evolutionary forces that 
selected for our larger brain size and increased longevity also contributed to 
vulnerability in our neural systems that lead to neurodegenerative diseases.  Given the 
increased incidence of neurodegenerative diseases with aging, one wonders why 
humans want to live so long without a guarantee of well-being.  Alternatively, the 
more we understand about these diseases, the closerwe come to prevention or at least 
effective intervention. 
There is no denying that the human body suffers wear and tear throughout the 





the average (Cevenini, Invidia et al. 2008; Willcox, Willcox et al. 2009; Guralnik and 
Kritchevsky 2010).  Overall, our goal will be to minimize the impact of many age-
related diseases of aging or perhaps even avoid persistent disease states altogether.  
Pathological pathways and mechanisms of age-related dis ases have been carefully 
studied and categorized by gerontologists over the years (Birren and Schaie 2006; 
Masoro and Austad 2006).   I hope that by contributing and expanding this 
knowledge will help to extend and improve the quality of life of our elders, and our 
own lives as we age.  
Future Directions 
The novel finding of increased norepinephrine in the striatum deserves further 
consideration and follow-up to determine the mechanism and utility.  While we did 
not observe motor deficits, the concurrent decrease of dopamine in striatum would 
potentially be harmful to an individual if maintained long term.   Deficits of 
dopamine in striatum are observed in cases of Parkinson’s disease, and this region of 
the brain is essential for controlling balance, movement and walking.    
Clearance of amyloid isoforms across the blood-brain b rrier mediated by 
low-density lipoprotein receptor and receptor for adv nced glycation end products 
also warrants further investigation.  Due to the higher incidence of cerebral amyloid 
angiopathy, the squirrel monkey would serve as a better model as this pathology was 
not observed in our rhesus monkey cohorts.  It is worthwhile to consider the relative 
ages between the squirrel and rhesus monkeys used in the current study; in order to 





rhesus monkey group would be beneficial toward assessm nt of age-related changes 








Table A.1: Greater than 60% reduction in prefrontal cortex, hippocampus, cingulate 





Figure A1. Increased pro-inflammatory cytokines in squirrel monkey brain.  30 
days following injection with DSP4 IL-6 and TNFα cytokines were elevated. IL-1β 
was not detected. 
 
Figure A2. Increased pro-inflammatory cytokines in rhesus monkey brain. 30 
days following IL-6 and TNFα cytokines were elevated in animals that received 




Pre-Frontal Cortex 72.24 78.11
Retrosplenial Cortex 91.52 97.37
Hypothalamus 32.17 3.24
Cerebellum 30.73 50.39
Locus Coeruleus 61.66 97.29






Figure A3. Increased pro-inflammatory cytokines in rhesus monkey 
cerebrospinal fluid.  Low levels of pro-inflammatory cytokines detected in 





Figure A4. Increased apoptosis in non-human primates. Measurement of Caspase 
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